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Abstract 
Stroke is one of the major causes of death and disability in developing countries. 
It takes place when the blood supply to a fraction of the brain is abruptly 
interrupted or severely reduced by, for instance, a blood clot. This is known as an 
ischaemic stroke. A number of studies indicate that deregulation of a set of cell 
cycle kinases has been implicated in neural death following an ischaemic insult 
and in neurodegenerative disorders. Overall the cyclin-dependent kinase 5 (Cdk5) 
and its two activators; the p35/p25 proteins, have been highlighted as critical 
players in neural survival, and potential mediators of angiogenesis. Hence, a 
detailed understanding of the mechanisms involving them in the pathogenesis of 
stroke can provide a platform for therapeutic intervention and potentially enable 
adoption of strategies to prevent the disease. The aim of the study was to identify 
key regulatory factors associated with Cdk5 signalling pathway during 
angiogenesis in a human brain microvascular endothelial cell line (hBMECs). 
Two cell clones of hBMECs were generated by stable transfection; 
overexpression of wild-type human Cdk5 and CIP (Cdk5 inhibitory peptide). Cdk5 
and p35 protein co-localisation were detected by Immunofluorescence analysis. 
The findings suggest that the ratio of p35/p25 is altered in favour of p25 by 
hypoxia. It was able to cleave p35 into a p25, which reduce the migration. The 
overexpression of Cdk5 increased the ratios of p35/p25 under hypoxic condition. 
Activation of p35/Cdk5 signalling occurred at the expense of p25-Cdk5, therefore, 
may have a protective role against endothelial cells apoptosis in hypoxia and 
xv 
positively contribute to preserving cell motility and the proper spatial and temporal 
control of cytoskeletal dynamics, which is essential for sprout formation 
(angiogenesis). Here it is shown that the protective roles of CIP are mediated 
through the down-regulation of HSP-70 and active caspase-3 and up-regulation 
of the phospho-extracellular signal-regulated kinase (p-ERK). CIP was able to 
protect hBMECs against apoptosis, and to allow angiogenesis to continue 
effectively during hypoxia. Therefore, it may be considered a potential future 
protector therapeutic after stroke and other brain injury.         
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Chapter 1 Introduction 
 
 
 
 
 
 
 
 
 
2 
1.1 Stroke 
Stroke is defined as a severe onset focal neurological event involving a vascular 
cause. It is the second highest cause of mortality around the world accounting for 
9% of deaths. The current 5.7 million stroke deaths are expected to increase to 7.8 
million by 2030 with 87% of all stroke mortalities occurring in low- and middle-income 
countries. Stroke mortality accounts for almost 50% of the total disease burden over 
the past ten years. The 30% increase in the number of patients suffering a first-ever 
stroke in the UK between 1983 and 2023 may be related to the ageing population 
and changes in cardiovascular disease risk factor profiles (Bornstein, 2009). This 
will increase the demand for specialised stroke medical facilities and costs to the 
healthcare authorities. Clinical and biomedical research can improve survival after 
stroke and decrease disabilities through medical interventions (Williams et al., 
2010). However, patients could survive with a reduced quality of life depending on 
the severity of their condition. There are a number of risk factors that are responsible 
for initiating the first stroke. These factors are categorised according to whether they 
are: (1) unmodifiable; (2) well recorded and modifiable, and (3) less well recorded 
modifiable. Unmodifiable risk factors include age, gender, family history, low birth 
weight and ethnicity. Modifiable risk factors include: cardiovascular disease, 
coronary heart disease, heart failure, peripheral arterial disease, hypertension, 
tobacco smoking, diabetes mellitus, asymptomatic carotid stenosis, atrial fibrillation, 
sickle cell anaemia, dyslipidaemia, high total cholesterol, low high-density 
lipoprotein cholesterol, dietary factors (sodium intake >2300 mg, potassium intake 
<4,700 mg), obesity, lack of physical exercise and postmenopausal hormone 
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replacement therapy. Less well recorded modifiable risk factors include: metabolic 
syndrome, alcohol abuse, hyperhomocysteinaemia, drug abuse, hypercoagulability, 
oral contraceptive use, inflammatory processes, migraine, high lipoprotein (a), high 
lipoprotein-associated phospholipase A2 and sleep apnoea (Johannes Binder, 
2012). Hypertension characterised by an increase in blood pressure (BP) above 
115/75 mmHg, is regarded as one of the most important risk factors leading to stroke 
with a higher prevalence in women at an older age, which accounts for 60% of all 
stroke events (Gorgui et al., 2014). This is possibly due to women having a longer 
life expectancy than men do. Diabetes is another major risk factor accounting for 
10-20% of all strokes (Sun et al., 2017), in particular, ischaemic strokes. The disease 
is part of a group of metabolic disorders characterised by hyperglycaemia. The 
abnormalities in insulin secretion, insulin action, or both that underline diabetes, 
leads to chronic hyperglycaemia, which is associated with long-term damage, 
dysfunction, and failure of various organs – particularly the eyes, kidneys, nerves, 
heart and blood vessels. Diabetes is also associated with hypertension and high 
blood cholesterol levels, increasing the risk of vascular disease. There are 
increasing cases of obesity and type II diabetes worldwide and hence the increasing 
incidence of strokes. 
The cause and location of the stroke determine its type, for instance, haemorrhagic 
stroke, ischaemic stroke, lacunar stroke, embolic stroke, young stroke, thrombotic 
stroke, spinal cord stroke, venous stroke, brain-stem stroke and cerebellar stroke 
(Ackerley et al., 2003). There are two main types of stroke (Figure1.1): 
haemorrhagic and ischaemic. Haemorrhagic stroke is characterised by a ruptured 
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vessel inside the skull leading to bleeding into the brain or the surrounding fluid. The 
occlusion of the blood supply to the brain is termed ischaemia stroke, where the 
insufficient blood supply to a region of the brain causes abnormal functioning of that 
brain tissue. Four out of every five cerebral strokes are ischaemic (Caplan, 
2010).The cause of ischaemic stroke is subdivided into three categories: 
thrombosis, embolism and decreased systemic perfusion. Thrombosis is defined as 
a process where an obstruction of the blood supply occurs due to a localised 
occlusion within one or multiple blood vessels. The lumen of the vessel is narrowed 
or occluded by a change in the vessel wall or by the formation of a clot. Embolism 
involves the formation of material originating from the aorta, carotid, and vertebral 
arteries or, from systemic veins in a different location within the vascular system 
blocking the lumen of an artery and preventing blood flow. The blockage of the artery 
is not caused by a localised process originating within the blocked artery, and hence 
is transient and may continue for hours or days before moving distally. The final 
category decreased perfusion, can arise from low systemic perfusion pressure due 
to cardiac pump failure (e.g. myocardial infarction or arrhythmia, and systemic 
hypotension) and as a result of blood loss or hypovolaemia, restricting the blood 
flow to the brain tissue (Caplan, 2009). 
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Figure 1-1 A representation of the two major types of stroke 
Adapted from http://fescenter.org/clinical-programs/current-clinical-trials/stroke-
programs. 
Intracerebral haemorrhage caused by unmanaged high blood pressure and cerebral 
amyloid angiopathy is characterised by a spontaneous rupture of small vessels, 
which accounts for approximately 80% of haemorrhagic strokes. In the elderly, 
cerebral amyloid angiopathy results from damage caused by the brain deposition of 
a molecule known as damage β-amyloid protein in the small and medium-sized 
blood vessels (Brunner et al., 2010). Subarachnoid haemorrhage is caused by a 
weakening of the arterial wall and is characterised by a rupture in an intracranial 
aneurysm, which accounts for about 20% of haemorrhagic strokes. Headache is a 
more common symptom of haemorrhagic stroke compared to ischaemic stroke. 
Other symptoms of haemorrhagic stroke include early loss of consciousness, 
vomiting and severely elevated blood pressure (Popp, 2011). 
6 
Ischaemic stroke and haemorrhagic stroke have similar symptoms, and it may be 
difficult to distinguish between the two types. It is also difficult to distinguish between 
hypoglycaemia, stroke because hypoglycaemia can produce focal neurological 
symptoms that resemble those of stroke. However, hypoglycaemia should be ruled 
out in all cases of suspected stroke, especially in known diabetics. Brain tumours 
and other intracranial masses (such as subdural haematomas) and stroke as 
hypoglycaemia can cause transient neurological deficits and other stroke-like 
symptoms. The location of the stroke can predict the pattern of associated 
symptoms. The ischaemic stroke has been associated with the absence of function 
such as loss of a single eye vision in an entire hemifield, numbness in part of the 
body, weakness or paralysis on one side of the body. Intracerebral haemorrhage 
has been shown to be associated with more severe neurological dysfunction, 
including weakness, numbness, vision loss, diplopia, dysarthria, gait disorder, 
vertigo, aphasia, or unconsciousness. The symptoms become worse when a small 
bleed (2 cm in diameter) increases in size in the first few hours of stroke (Alway and 
Cole, 2009). 
The diagnosis of acute stroke includes history taking, clinical examination, acute 
brain and cardiovascular imaging and basic laboratory tests. Brain imaging, 
Computerised tomographic (CT) or Magnetic resonance imaging (MRI) are 
considered reliable techniques to differentiate between ischaemic stroke and 
intracerebral haemorrhage. CT can be utilised to detect early abnormalities following 
a large ischaemic stroke involving the cortex or basal ganglia within 1-3 hours, 
whereas longer periods (12-24 hours) are required to visualise small and brainstem 
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strokes. MRI has a higher resolution, faster appearance of abnormalities and 
improved brain-stern imaging over CT for the detection of acute stroke, while 
perfusion-CT has been used for early ischaemic attack and reliably differentiates 
between reversible and irreversible ischaemia (Fisher, 2009). The management of 
acute stroke involves rehabilitation, avoidance of adverse outcomes in the sub-
acute setting and administration of intravenous tissue plasminogen activator (tPA). 
The limited treatment window (3 hours) of tPA requires early patient arrival and early 
detection (Goldstein, 2011).  
 
1.2 Pathophysiology of Acute Ischaemic Stroke 
Ischaemic stroke is a heterogeneous disorder caused by one of two pathogenic 
mechanisms: 1) atherosclerotic disease of large or small vessels and 2) embolism. 
Different areas of the brain may have varying susceptibilities to ischaemic injury 
(Aronowski et al., 1999). Atherosclerosis in small vessels (lacunar infarct) accounts 
for up to 25% of all ischaemic strokes (Shi and Wardlaw, 2016). Cerebral ischaemia 
or infarction is characterised by an impaired cerebral blood flow (CBF) resulting from 
an obstruction of the blood flow in a main cerebral vessel (often the middle cerebral 
artery). leading to the local deprivation of both oxygen and glucose is leads to a 
central core of dead and irreversibly damaged neurons within minutes of ischaemic 
onset (Kaufmann et al., 1999). The volume of the brain infarct is determined by the 
area of the ischaemic penumbra. This is a region of viable ischaemic tissue perfused 
with over 20-25% of regular blood flow to maintain function and morphologic integrity 
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(10-12ml/100g/min) around the infarcted core, where electrical activity is not lost 
(Olsen et al., 1983; Heiss, 2000). In contrast, the core is hypoperfused at less than 
18-20ml/100g/min and is at risk of dying within several hours (Gusev and 
Skvortsova, 2003a). The normal brain tissue that immediately surrounds the 
ischaemic tissue is less likely to die, as it is perfused at only slightly below the 
minimal normal rate of 60ml/100g/min. 
While the ischaemic core suffers irreversible loss of ion homeostasis, the insult in 
the penumbra is either milder or of shorter duration, because of sub-optimal blood 
flow in arterioles, capillaries and collateral vessels. These neurones in the penumbra 
are unable to maintain normal function but can be saved if reperfusion is achieved 
in time. However, if the blood flow drops below the critical level (10-15ml/100g/min), 
they do not return to normal, leading to the cessation of their activity, primary 
neuronal death and expansion of the infarct zone. In the ischaemic penumbra 
(continued ischaemia), the activation of several death pathways leads to secondary 
neuronal death and tissue necrosis promoting the stabilisation of the clinical deficits. 
Thus maintaining a minimal blood flow through e.g. thrombolytic treatment to the 
infarcted core and penumbra can preserve the cellular energy haemostasis and 
decrease the final infarct volume (Belayev et al., 2012).  
Brain ischaemia involves changes in signalling, signal transduction, metabolism, 
and gene regulation/expression at a cellular level. Cerebral ischaemia involves the 
obstruction of cerebral blood flow regularly resulting in a reduction in ATP 
availability, rapid failure of membrane ionic pumps and loss of homeostasis, the 
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release of excitotoxic neurotransmitters (glutamate), and the consequent neuronal 
calcium ion excess that activates a series of highly detrimental enzymatic cascades 
within 1 or 2 hours. The formation of free radicals such as Nitric oxide (NO) can 
cause cellular injury through the degeneration of cytoskeletal proteins, loss of 
cellular membrane integrity and deoxyribonucleic acid (DNA) degradation. These 
events lead to apoptotic or necrotic death. Brain injury leads to the upregulation of 
neurodestructive, and pro-inflammatory (l-1B, TNFα) gene expression. This leads 
to excitotoxicity, peri-infarct depolarisation, inflammation and apoptosis causing 
damage within the ischaemic penumbra, which plays a critical role in the 
pathophysiology of stroke (Dirnagl et al., 1999) and ischaemic neuronal death 
(Gillardon et al., 1999). A more in-depth understanding of the cellular and molecular 
mechanisms that promote recovery or prevent acute stroke is required to prevent 
delayed ischaemic neuronal death. One way is to enhance the activity of 
endogenous neuroprotective mechanisms to inhibit toxic pathways, inflammation 
and apoptosis. It is the balance between these pathways that determines the fate of 
the tissue at risk. 
 
1.3 Excitotoxicity 
Glutamate plays a vital role in a) the processing of events occurring in regular 
sequence and b) neuronal plasticity. It is released from presynaptic terminals to 
allow Na+ and Ca2+ influx through N-methyl-D-Aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and/or kainate receptors 
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leading to membrane depolarisation; an increased and/or additional activation of 
receptors due to uncontrolled release of glutamate in ischaemic areas results in 
neuronal death (glutamate excitotoxicity). The glutamate-calcium cascade is 
initiated by the interaction of glutamate with the NMDA receptor (permeable to Ca2+, 
Na+, K+ and H+), which induces a calcium-mediated focal hypoxic-ischaemic 
necrotic lesion (Gwag et al., 2002) and the formation of brain infarction (Gusev and 
Skvortsova, 2003b).The activation of NMDA receptors (Koh et al., 1990) and 
calcium influx can cause neuronal death after focal cerebral ischaemia that is 
accompanied by temporary (30-60 min) elevation of extracellular glutamate (Liu et 
al., 2009), while Na+ influx contributes to the swelling of neuronal cell bodies (Zhang, 
2016). Since an energy-dependent mechanism is responsible for the export of Ca2+ 
from the cytoplasm (100nM, 1/10,000 of that in the extracellular matrix) to the 
extracellular compartment in neurons (Wright, 2013), energy failure in the ischaemic 
brain during hypoxia, results in passive efflux of K+ from cells, enhancing Ca2+ entry 
and its release into neurons (Gusev and Skvortsova, 2003b). The resulting elevated 
levels of intracellular cytoplasmic Ca2+ lead to oxidative stress (Leker and Shohami, 
2002) and glutamate excitotoxicity of biochemical processes resulting in further 
injury (Budd, 1998) (Figure 1.2). DNA, lipids and protein damage can be secondary 
to Ca2+ dependent effector protein activity due to prolonged elevation of Ca2+ levels. 
These include; endonucleases, phospholipases, lipases, protein kinases and 
proteases that may cause damage. 
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Figure 1-2 Schematic model of cell death caused by excitotoxicity 
The schematic flow chart demonstrates the excitotoxic cell death scheme in ischemic brain 
injury and basic mechanisms of glutamate-calcium cascade through which excitotoxicity 
results in necrotic cell death after ischemic stroke.   
 
1.4 Inflammation 
The inflammatory response in cerebral ischaemia is characterised by the activation 
and release of cytokines, chemokines, endothelial-leukocyte adhesion molecules 
and proteolytic enzymes, exacerbating tissue damage for several days after the 
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onset of symptoms (Shukla et al., 2017). Following acute focal ischaemia, pro-
inflammatory cytokines such as tumour necrosis factor α (TNFα) and interleukins IL-
6 and IL-1 (Kim et al., 2014) are produced by astrocytes, microglia, leukocytes and 
endothelial cells (Lakhan et al., 2009) and lead to a local inflammation in the brain 
lesion and subsequently inflammation causes more damage and increases the 
infarct volume (Gusev and Skvortsova, 2003b). Peripherally cytokines derived from 
phagocytes, T-lymphocytes, natural killer cells and polymorphonuclear leukocytes 
can exacerbate central nervous system inflammation and gliosis (Barber et al., 
2003). Shortly after an ischaemic attack, inflammatory intermediaries are 
upregulated in the presence of damaged tissue. Due to their role in brain tissue 
damage, pro-inflammatory cytokines expressed within the first 2 hours after the 
onset of ischaemia remain significantly elevated for several days after stroke onset 
(Jin et al., 2010). This presence of proinflammatory cytokines during an acute stroke 
has deleterious effects on the outcome of cerebral ischaemia; including cerebral 
infarction (Fassbender et al., 1994; Tarkowski et al., 1995; Vila et al., 2000) and 
increased cardiovascular risk (Zhou et al., 2013). For instance; brain ischaemia has 
been suggested to be associated with the expression of a number of inflammatory 
cytokines (IL-1 and TNFα) and chemokines [IL-8, monocyte chemoattractant 
protein-1 (MCP-1), β-chemokine Regulated upon Activation, Normal T-cell 
Expressed and Secreted (RANTES) and interferon-γ-inducible Protein, and up-
regulation of adhesion molecules [intercellular adhesion molecule-1 (CAMI) 
selectins], which maintain leukocyte recruitment to the vascular endothelium 
(Feuerstein et al., 1998; Ramesh et al., 2013). The expression of chemokines is 
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upregulated in the ischaemic territory. These chemokines aid the infiltration of 
inflammatory cytokines into the ischaemic sites (Mirabelli-Badenier et al., 2011). 
Cytokines such as TNFα and IL-1β have involved in the propagation and 
maintenance of the brain inflammatory response to injury acting as a 
chemoattractant to leukocytes. Thus, the chronic exposure of damaged brain tissue 
to TNFα and IL-1β may promote neuronal survival. Given both potential deleterious 
and beneficial effect of elevated cytokines and associated inflammation, the net 
effect of inflammation during stroke still needs to be established. 
Adhesion molecules such as CD11/CD18 integrins, ICAM1ELAM1, P-selectin and 
tissue matrix metalloproteinases (MMPs) have been shown to be expressed early 
after the insult (Kim et al., 2014) and act to facilitate penetration of leukocytes 
through the blood-brain barrier (Pantoni et al., 1998; Del Zoppo et al., 2000). Thus, 
the suppression of postischaemic inflammation through antibodies against adhesion 
molecules neutrophil depletants, inhibitors of proinflammatory cytokines, and anti-
inflammatory cytokines (Clark and Zivin, 1997; Spera et al., 1998; Dietrich et al., 
1999; Ooboshi et al., 2005) may provide therapeutic strategies for acute stroke 
patients. In response to continued proinflammatory cytokine production, 
lymphocytes and monocytes/macrophages act to secrete anti-inflammatory 
cytokines such as IL-10 and IL- 4 in a feedback loop to block and inhibit inflammatory 
cytokine production (Tedgui and Mallat, 2001). These anti-inflammatory cytokines 
may have neuroprotective effects in reducing the infarct volume following the 
ischaemic attack (Bonaventura et al., 2016) (Figure 1.3). 
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Figure 1-3 Schematic diagram illuminate the cytokines interacted during 
inflammation 
Inflammatory pathways associated with acute ischemic stroke, which stimulates expression 
of nuclear transcription factors. Subsequent synthesis of pro-inflammatory cytokines and 
chemokines, together with adhesion molecules expression, cause migration of leukocytes 
and lymphocytes to the infarcted area resulting in inflammation. 
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1.5 Apoptosis 
Apoptosis or programmed cell death is an energy-dependent biochemical 
mechanism through which cell death occurs. It is a highly cell-specific process, and 
it may be induced in damaged cells where the damage is beyond repair (Rastogi 
and Sinha, 2010). Hence, it is involved in normal cell turnover, proper development 
and functioning of the defence system, hormone-dependent atrophy, embryonic 
development and cell death caused by chemicals. Disruption in the process of 
apoptosis may lead to diseases such as ischaemic damage (Figure1. 4), 
autoimmune disorders and various types of cancer (Elmore, 2007).In apoptosis, the 
extrinsic pathway is mediated by a sub-group of tumour necrosis death factor 
receptors (TNFRs) a superfamily that includes TNFR, Fas and TRAIL (Portt et al., 
2011). Upon activation via death signals, the latter receptors form the death-
inducing signalling complex (DISC) activate caspase 8, which in turn activates 
caspase 3. The stimulation of death receptors can also activate the intrinsic 
apoptotic pathway, controlled by members of the BCL-2 family. This occurs when 
caspase 8 cleaves BID to t-BID, that then interacts with BAX within the mitochondria 
leading to the leakage of cytochrome c and via the formation of the apoptosome to 
activation of caspase 9 (Chiong et al., 2011). Both extrinsic and intrinsic pathways, 
resulting in the same outcome; the activation of a cascade of proteolytic enzymes, 
members of the caspase family (Sprick and Walczak, 2004). 
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Figure 1-4 A representation of the two major apoptotic pathways; the extrinsic 
and the intrinsic pathway 
The death-receptors activate the extrinsic pathway that acts through caspase 8 or the 
mitochondrial intrinsic pathway. The intrinsic pathway activates caspase-activating complex 
(which includes cytochrome c and apoptosis-activating factor 1, APAF1) that acts on 
caspase 9, which in turn activates caspase 3. These pathways are regulated by BCL2 and 
the inhibitor of apoptosis IAP protein families, respectively. BCL2 proteins are believed to 
regulate the mitochondrial permeability promoting BID and cytochrome c release (Andersen 
et al., 2005). 
 
1.6 Apoptosis after Stroke 
Ischaemia-induced programmed cell death was suggested to occur in neurones 
(D'amelio et al., 2010), vascular endothelial cells and non-neuronal cells that 
constitute the ischaemic core. The restricted blood flow after cerebral ischaemia is 
a key factor leading to the disruption of the blood-brain barrier integrity, the 
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regulation of arterial tone and apoptosis (Hu et al., 2017). The mechanism of 
apoptosis is thought to be mediated via caspase-3 and several other caspase family 
members, which have been reported to be activated in astrocytes and microglia after 
middle cerebral artery occlusion (Chen et al., 1997; Krupinski et al., 2000). Following 
cerebral ischaemia, the caspases cause the breakage of DNA strands within the 
border zone of astrocytes in infarcted tissue (Chen et al., 2011) leading to apoptosis. 
For instance, evidence suggests that the mechanism of apoptosis in cerebral 
endothelial cells of basilar arteries after subarachnoid haemorrhage involves TNFR1 
and the caspase-8 and caspase-3 pathways. This was mainly colocalised DNA 
fragmentation and either caspase-3, caspase-8 or TNFR1 (Zhou et al., 2004). 
Another mechanism of apoptotic death after stroke may involve the generation of 
ROS e.g. due to blood reperfusion after stroke (Shirley et al., 2014; Kalogeris et al., 
2014). Reactive oxygen species (ROS) may react with vascular endothelium-
derived nitric oxide to form the highly toxic peroxynitrite radical initiating the process 
of apoptosis in vascular cells after ischaemic stroke (Rodríguez-Yáñez et al., 2006). 
One approach to improving neuron survival after stroke may involve the use of 
SMND-309, a novel neuroprotective metabolite of salvianolic acid, which can 
prevent neuronal cell death via the activation of the PI3K/Akt/CREB-signalling 
pathway (Wang et al., 2016). 
18 
 
Figure 1-5 A schematic diagram represents the CDK5 signalling pathways 
Schematic diagram showing the role of PI3K signalling pathways via receptor interactions, 
resulting in the downstream disruption of processes involved in regulating CDK5 integrity. 
PI3K is upstream of cdk5/p35, and its activation can lead to an increase in p35 protein 
levels, and some other factors might ameliorate these effects by antagonising the activation 
of PI3K by cellular neurotoxins. PI3K and CDK5 share several downstream targets (e.g. 
Tau), and simultaneous activation of both of these pathways may exacerbate the neurotoxic 
effects of proteins involved in stroke. Adapted from Crews et al (Crews et al., 2009). 
 
1.7 Neuroprotection 
Some mediators induced in the peri-lesional zones contribute to cellular death, while 
others such as heat shock proteins (HSPs), anti-inflammatory cytokines and 
endogenous anti-oxidants may counteract ischaemic damage and improve neuronal 
repair. The targeting of these survival-promoting mechanisms could be used in the 
19 
development of new therapeutic strategies. The expression or upregulation of HSPs 
such as HSP70, HSP72 and HSP27 can be triggered by various harmful stresses 
including ischaemia within 1-2 hours and then downregulated after 1-2 days (Sharp 
et al., 2013). They can act to prevent the aggregation of denatured proteins by 
allowing their refolding to the correct tertiary structures preventing protein 
denaturation (Leker and Shohami, 2002). Studies have indicated that anti-
inflammatory cytokines, such as IL-1 receptor antagonist (IL-1 ra) and IL-10, may 
protect against ischaemic damage by inhibiting the production of pro-inflammatory 
cytokines (Kim et al., 2014; Wang et al., 2015). Neuroprotective growth factors 
increase after 1-3 hours after stroke, with a peak at 12 hours, and complete 
downregulation by 2-3 days (Chodobski et al., 2011). They induce signal 
transduction pathways leading to multiple transcription factors of genes involved in 
neuronal cell survival and proliferation. 
A number of growth factors such as Nerve growth factor (NGF), Brain-derived 
neurotrophic factor (BDNF), fibroblast growth factor (FGF) and Transforming growth 
factor (TGF) are induced early after brain lesions. It has been suggested that these 
have a protective role in preventing apoptotic death (Leker and Shohami, 2002). 
They interfere with the apoptotic pathways through the PI3K/Akt, Ras/Mitogen-
activated protein kinases (MAPKs), or both (Mendoza et al., 2011). The activation 
of glutamate receptors leads to the production and release of BDNF, which signals 
through the PI3K/Akt or Ras/MAPK pathway. PI3K activates the serine-threonine 
kinase Akt, which is translocated to the nucleus, where it phosphorylates to 
inactivate its target. Neurotrophins and other growth factors such as PI3K/Akt-
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activated kinases promote cell survival by phosphorylating and inactivating the pro-
apoptotic factor BAD via the Ras MAPK signalling pathway (Morrison et al., 2003). 
 
1.8 Angiogenesis 
Angiogenesis or neovascularisation is the process of generation of new blood 
vessels from a pre-existent vascular system. Revascularisation and reperfusion 
events can determine tissue survival and patient recovery after stroke. Angiogenesis 
plays a key role in allowing neuronal reorganisation and survival after stroke (Slevin 
et al., 2006). Angiogenesis involves the new vessel formation from endothelial cell 
(EC) sprouts, emanating from pre-existing vessels using angiogenic and anti-
angiogenic factors that act to drive the recruitment, migration, proliferation and 
differentiation of ECs (Munoz-Chapuli et al., 2004). Angiogenesis is controlled 
spatially and temporally by focal adhesions and activation of cytoskeletal organisers, 
which regulate cellular mechanical forces and plasticity during migration, sprouting 
and cell differentiation (Avraham et al., 2003). During pathological processes, 
angiogenesis aid tumour growth, metastasis, inflammation and ocular disease 
(Mehta and Dhalla, 2013). The process of angiogenesis is initiated by endothelial 
cells, which line all blood vessels and constitute virtually the entirety of capillaries 
(Auerbach et al., 2003). Endothelial cells initially proliferate, selectively break down 
the basement membrane and adjacent extracellular matrix, migrate to the site and 
begin tube formation. Following tube formation, endothelial cells go through tissue-
specific alterations to produce functionally distinct vessels (Figure 1.6). 
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Angiogenesis can occur at the embryonic level, where endothelial cell precursors 
(angioblasts) differentiate and associate to form primitive vessels in a process called 
vasculogenesis (Hoeben et al., 2004). Vasculogenesis is the de novo formation of 
a vascular network during embryonic development and growth. Angiogenesis or 
arteriogenesis can also occur in pre-existing vascular networks, where it is involved 
in the remodelling of pre-existing arterial vessels to form arteries. During 
arteriogenesis, ECs respond to angiogenic stimuli such as chemokines or growth 
factors, and increases in the diameter of vessels are mediated by the increased 
stress that is induced by elevated pressure rates in arteries, leading to thicker 
arterial walls. The balance between the activating and inhibiting signals of 
angiogenesis including cytokines, hormones, endothelial cell migration, circulating 
progenitor cells and destabilisation of the vessel wall, the basal lamina, the 
interstitial matrix, and chemical signals from cancer cells, regulate the latter process 
(Multhoff et al., 2014).ll 
 
Figure 1-6 The formation of the arterial network 
Angiogenesis by pericytes and vascular smooth muscle cells (Cao, 2010). 
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During ischaemia, angiogenic factors, such as FGF and VEGF, (Losordo and 
Dimmeler, 2004) are upregulated are mobilised to induce vascular growth. These 
factors act on endothelial cells to stimulate proliferation, migration and tube 
formation and make endothelial cells less sensitive to the induction of apoptosis. 
(Mehta and Dhalla, 2013). Angiogenesis can also occur in response to ischaemia in 
non-CNS tissues. A number of disorders can activate endogenous angiogenesis: 
including myocardial infarction and limb, hence, drugs that enhance angiogenesis 
can reduce injury in ischaemia. The regulatory mechanisms in the brain that trigger 
angiogenesis may involve hypoxia-inducible factor (HIF) pathways. 
Even though the VEGF-induced angiogenesis results in vessels that are 
haemorrhagic, aggravating inflammatory responses in the recovering area 
surrounding an ischaemic event (Baeten and Akassoglou, 2011; Obermeier et al., 
2013). The formation of these new blood vessels in areas surrounding the stroke 
site has been shown to be associated with longer survival in stroke patients, 
suggesting the benefits of angiogenesis for the ischaemic brain. 
 
1.8.1 Mechanisms of Angiogenesis after Stroke 
Angiogenesis is described as the growth of new blood vessels and as a key occurs 
during both physiological and pathological conditions (Carmeliet et al., 2001; Collen 
et al., 2001; Conway et al., 2001). Angiogenesis is vital for the development of new 
microvessels after stroke (Slevin and Krupinski, 2009). In the acute phase after 
stroke, thrombolytic reperfusion with recombinant tissue plasminogen activator is 
used in fewer than 5% of ischaemic stroke patients worldwide. Treatments involving 
23 
rehabilitation contribute in small part to recovering chronic ischaemia patients 
(Shuaib and Hussain, 2008). Mechanisms that promote neurogenesis and 
angiogenesis may provide a novel target for brain repair (Greenberg and Jin, 2005; 
Zhang et al., 2005; Chopp et al., 2008). Neurovascular remodelling is a key 
component in strokes. The collaboration between growth factors, adhesion molecule 
modifiers and cellular therapies may provide the optimal approach for promoting 
angiogenesis in the brain (Ma et al., 2012). 
 
1.8.2 Cdk5 
Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/threonine kinase that 
is highly expressed in neuronal cells in the central nervous system (Kanungo et al., 
2009). Unlike other Cdks, Cdk5 is not active in cell cycle regulation but is involved 
in a wide range of neuronal functions, including nervous system development, 
neuronal differentiation and survival (Chappell et al., 2011; Chillakuri et al., 2012). 
Under physiological conditions, Cdk5 activity is primarily restricted to postmitotic 
neurons and involved in the modulation of signalling pathways that control neurite 
outgrowth, neuronal cell adhesion, neuronal migration (Contreras-Vallejos et al., 
2012), neural cytoskeletal organisation and synaptic activity and neuronal survival 
(Liebl et al., 2010; Chappell et al., 2011; Chillakuri et al., 2012; Yin et al., 2012). In 
instances where Cdk5 is degraded, it leads to neuron cell death under normal as 
well as pathological conditions (Ikeda et al., 2000; Rajdev et al., 2000; Glading et 
al., 2002; Potthoff et al., 2007; Kanungo et al., 2009)  either directly or in an indirect 
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manner. On the other hand, in the presence of various neurotoxic insults, including 
brain ischemia and oxidative stress, Cdk5 is hyperactivated with potentially fatal 
consequences in respect to neuron cells (Ikeda et al., 2000; Rajdev et al., 2000; 
Glading et al., 2002; Liebl et al., 2010) emphasising that appropriate control of Cdk5 
activity is crucial for normal cellular homeostasis (Kanungo et al., 2009). Evidence 
demonstrates that a crucial determinant of Cdk5 activation is the protein-protein 
interactions with its two regulatory partners p35 and p25 (Kanungo et al., 2009). The 
increase in intracellular calcium in a neuronal cell undergoing apoptosis (due to 
physical pressure and/or lack of blood supply) induces the production and release 
of calpain to the surrounding tissue (Walker and Tesco, 2013). The activation of 
calpain was demonstrated to increase the cleavage of p35 into p25 peptide in the 
endothelial cells of the ruptured blood vessel. The increase in the p25/p35 ratio was 
suggested to lead to the hyperactivation of Cdk5 (Glading et al., 2002; Liebl et al., 
2010). This may play a role in the process of neo-blood vessel generation at a later 
stage. Conversely, an inhibition of p35 cleavage can confer neuron protection ( 
Zhang et al., 2012), thus, further demonstrating the role of p25 as a marker for 
neuronal damage (Figure 1.7). 
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Figure 1-7 Activation mechanism of Cdk5 
Cdk5 possesses an inactive catalytic subunit, which can become activated by the p35 Cdk5 
activator. Upon activation, Cdk5 is recruited to membranes via p35 association with the 
myristoylation of its N-terminal region. The p35 protein has a short life span due to its 
susceptibility to proteasomal degradation. Under conditions of neuronal stress or death, 
calpain is activated, where it cleaves p35 into a p25 C-terminal fragment. p25 has a longer 
half-life, and it acts via the phosphorylation of membrane proteins making cdk5 hyperactive. 
p10 (a cleaved product of p35) is regarded as a Cdk5-specific inhibitor (Kimura et al., 2014). 
 
Because of its philological activity, Cdk5 may be a potential drug target to treat brain 
injury. The currently available Cdk5 inhibitors have a poor selectivity and specificity 
as they inhibit off-target Cdks with equal or higher potency causing serious side 
effects. Developing Cdk5-specific inhibitors such as p10 (the cleaved product of 
p35), which selectively abrogate the interaction of Cdk5 with p25, but not with p35, 
may prevent neurotoxicity and increase the likelihood of neural survival (Zhang et 
al., 2012). Likewise, it has been shown that Cdk5 inhibitory peptide (CIP), a 125 
amino acid fragment of p25 (Zheng et al., 2002), is effective in inhibiting the 
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hyperactivation of Cdk5–p25 in vivo (Sundaram et al., 2013) resulting in a 
subsequent reduction in the neurodegenerative pathologies caused by deregulation 
of Cdk5-p25 without compromising normal neurodevelopment. 
 
1.8.3 p35 
p35 is regarded as a Cdk5 activator that forms a tertiary structure that is similar to 
the cyclin-box fold domain, although the primary sequence of p35 is distinct from 
that of cyclins (Liu et al., 2017). The Cdk5-p35 complex has a ternary structure 
similar to the complex between Cdk2 and cyclin A (Cdk2–cyclin-A) (Tarricone et al., 
2001). p35 is a membrane-anchored protein containing an N-terminal domain 
encompassing the p10 component and a C-terminal domain containing p25 with a 
short half-life (t1/2 = 20-30 minutes). The p25 domain is responsible for binding Cdk5 
leading to its activation, while the p10 domain contains the myristoylated region that 
is used to guide cdk5 to the plasma membrane. The p10 domain also contains a 
signal for p35 degradation through the ubiquitin-proteosome pathway. p35 is rapidly 
degraded in neurons bearing Cdk5 activity (Wei et al., 2005). The active form of 
Cdk5 also autoinhibits its activity through p35 phosphorylation specifically at amino 
acid residues Ser8 and Thr138 (hereafter S8 and T138, respectively). The 
phosphorylation events of p35 are differentially regulated and have different 
consequences (Kamei et al., 2007). The phosphorylation level of S8 is constant 
during development, whereas T138 phosphorylation is highest in the foetal brain but 
not so in the adult brain. Since both sites are phosphorylated by Cdk5, the 
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differential phosphorylation levels are believed to be due to dephosphorylation of 
T138 in the adult brain by protein phosphatase 1 (PP1) or protein phosphatase 2A 
(PP2A) (Kamei et al., 2007). 
 
1.8.4 P25 
p25, the truncated form of p35, is known as a neuron-specific activator of Cdk5 
(Shah and Lahiri, 2014). It is generated from p35 under neurotoxic conditions, such 
as exposure to excitotoxicity, ischaemia and oxidative stress (Patrick et al., 1999; 
Sahlgren et al., 2006). Neurotoxin insults disrupt intracellular Ca2+homeostasis in 
neurons, thereby activating calpain, which in turn cleaves p35 into p25 (Lee et al., 
2000). The ability of p25 to activate or hyperphosphorylate Cdk5 may be attributed 
to the prolonged half-life of p25 compared to p35 (Zhang et al., 2013) and the 
resistance to ubiquitin-mediated proteolysis. The modification of Cdk5 may disrupt 
its normal physiological function and lead to the damage of the brain cells leading 
to neuronal toxicity. The Cdk5-induced neurotoxicity may have also been promoted 
by the ability of the Cdk5-p25 complex to translocate from the plasma membrane to  
the cytosol and the nucleus allowing the access of Cdk5-p25 to a variety of targets 
as opposed to the Cdk5-p35 complex, which localises primarily to the perinuclear 
region and the plasma membrane with minimal distribution in the nucleus (Fu et al., 
2006; Asada et al., 2008). 
Targets for the Cdk5-p25 complex include; GM130, peroxiredoxin 1, peroxiredoxin 
2, lamin A, lamin B1, Cdc25A, Cdc25B and Cdc25C (Sun et al., 2008; Sun et al., 
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2009; Chang et al., 2010; Chang et al., 2011; Chang et al., 2012). The 
phosphorylation of GM130 by the Cdk5-p25 complex may cause abnormal Golgi 
fragmentation leading to the phosphorylation of peroxiredoxins (Sun et al., 2008) 
and hence oxidative stress. The latter mechanism triggers the phosphorylation of 
lamins, Cdc25A, Cdc25B and Cdc25C resulting in the dispersion of the nuclear 
envelope and abnormal activation of the cell cycle (Chang et al., 2011; Chang et al., 
2012). Under physiological conditions, Cdk5 also act via the phosphorylation of 
neurofilament heavy chain (NF-H) at its tail domain on Lys-Ser-Pro motifs. This aids 
the assembly of neurofilaments within the axon, resulting in axonal support and 
neurite outgrowth (Wang et al., 2012). However, under neurotoxic conditions, Cdk5-
p25 was shown to hyperphosphorylate tau, which aggregates in cell bodies to form 
neurofibrillary tangles in several neurological disorders. Thus, the Cdk5-p25 
complex-mediated toxicity is caused by the hyperphosphorylation of its physiological 
targets, and phosphorylation of non-physiological targets (Bano and Nicotera, 
2007). 
 
1.8.5 CIP-Peptide Promotes Angiogenesis in hypoxia condition 
Evidence suggests the neuronal cytoprotective role of a small natural peptide (CIP-
peptide) under neurotoxic stress. CIP has been identified as a derivative of the p35 
cleavage peptide, which selectively targets the Cdk5/p25-dependent pathway 
(Kesavapany et al., 2007). CIP’s role(s) are thought to be mediated through the 
selective inhibition of Cdk5/p25 activity without affecting the Cdk5/p35 signalling 
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pathways. CIP’s role is implicated in increased p35 localisation with actin fibres and 
therefore the stabilisation of the actin cytoskeleton. The latter phenomenon leads to 
increased recovery of cell spreading and the formation of stable neo-capillaries. 
Thus, the p35/Cdk5 signalling pathway may in part have an autoprotective role 
during in vitro angiogenesis. Hence, CIP may act as a vascular protector supporting 
tissue remodelling after ischaemic stroke (Kesavapany et al., 2007). 
 
1.8.6 Brain Ischaemia and Calcium 
The inability to clear excitatory amino acids can cause sustained gating of receptor-
operated channels (Gillessen et al., 2013) with prolonged neuronal depolarisation 
leading to calcium overload and ultimately a neuronal loss in the ischaemic brain. 
Inflammatory response and necrotic cell death can be triggered by excitotoxic 
stimulation within ischaemic regions, depending on the intensity of the insult 
(Northington et al., 2011). For instance, glutamate overstimulation of glutamate-
ionotropic receptors at synaptic and extra-synaptic sites causes prolonged neuronal 
depolarisation that triggers the deregulation of intracellular calcium and sodium ion 
homoeostasis. This leads to apoptosis and in severe cases (Carvajal et al., 2016), 
where there is a widespread excess glutamate may cause necrosis. Hence, 
treatments aimed at reducing ion imbalance by blocking the gating of ionotropic 
glutamate receptor and voltage-gated channels can reduce brain infarct (Li et al., 
2014). Calpains cleave the sodium-calcium exchanger (NCX). The Ca2+ extruding 
systems such as sodium-calcium exchangers (NCXs) are important for the Ca2+ 
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efflux from neurons (Figure1.8). NCXs have been shown as fundamental players 
during ischemia (Pignataro et al., 2007; Pignataro et al., 2011) and neuronal 
degeneration (Sisalli et al., 2015). NCX3, in particular, has been shown to be 
essential in the maturation of dissociated neurons (Gomez-Villafuertes et al., 2005) 
and in the control of intracellular Ca2+ in skeletal muscle fibres (Sokolow et al., 
2004). In response to an excitotoxic stimulus such as high glutamate concentrations, 
calpains act by cleaving one of the major isoforms (e.g. isoform 3) of the NCX or 
NCX3. The cleavage of NCX3 inhibits its capability to remove accumulated Ca2+ 
and precludes the possibility to restore Na+/Ca2+ exchange leading to a massive 
Ca2+ overload (irreversible build-up of the intracellular Ca2+ concentration) and 
neuronal degeneration (Jin et al., 2014). In addition, caspases can affect the activity 
of the plasma membrane Ca2+ ATPase (PMCA), perhaps through the glutamate-
mediated pathway, via its internalisation and cleavage (Andersen et al., 2016). The 
internalisation of PMCA contributes to the deregulation of Ca2+ and causes neuronal 
death. Hence, there is a link between calcium-dependent proteases, calcium 
overload and neuronal degeneration after an excitotoxic insult. The studies relating 
to calpains and caspases highlight the important role of Ca2+ transporters in 
neuronal demise (Pottorf et al., 2006) and provide potential pharmacological targets 
to prevent extensive neuronal demise during the stroke.  
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Figure 1-8 The Interaction between Calcium and Calpains – possible 
modulation effects 
The entrance of Ca2+ by binding to NMDA and probably other channels initiates the increase 
in excitotoxic Ca2+. Calpains are activated and cleave NCX3 prevents the restoration of 
Na+/Ca2+ exchange, therefore this results in an irreversible accumulation of the intracellular 
Ca2+concentration. Adapted from (Bano and Nicotera, 2007). 
 
1.8.7 Gamma secretase inhibitor (DAPT) 
Due to their shared roles in neuronal cell development and the phosphorylation, the 
relationship between Notch and CdK5 was established by the use of a Notch 
inhibitor, N-[N-(3,5-difluorophenacetyl)-1- alanyl]-S-phenylglycine t-butyl ester 
(DAPT) on Cdk5 expressing-cells (Kanungo et al., 2008). The use of roscovitine 
may inhibit the activity of Cdk5 activity in a different way to DAPT. Previous studies 
using 10 µM DAPT attenuated Cdk5 catalytic activity and reduced p35 bioavailability 
while upregulating Cdk5 expression at the transcriptional level. Also, the neuronal 
cytoskeletal proteins phospho-tau and phospho-neurofilament, normally 
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phosphorylated by Cdk5 showed a shift in their localisation from axons to cell bodies 
in DAPT-treated cells, suggesting a role for the Notch signalling and Cdk5 
expression in regulating neuronal cytoskeletal protein dynamics. The action of 
DAPT was opposed by an over-expression of p35, which restored Cdk5 activity 
through direct interaction. Thus, DAPT action does not disrupt Cdk5 and p35 
interaction and the latter is dependent on the levels of p35 within the cell, as well as 
its effects on regulating the expression of Cdk5 by inhibiting its activity (Tanaka et 
al., 2001; Joshi et al., 2014). 
 
1.8.8 Signalling Pathway and Targets of Cdk5 
Cdk5 has a role in the determination of the fate of neurons and ECs during the 
stroke. Cdk5 could be seen as a master switch controlling both neuronal survival 
and revascularisation. The action of Cdk5 is dependent upon its interaction with a 
number of substrates; namely the myocyte enhancer factor-2 (Mef2), caspase-3, 
Tau and p53 (Slevin and Krupinski, 2009; Slevin et al., 2015). Cdk5 has also been 
found in association with the cytoskeletal protein actin in ECs and potentially 
stimulates EC migration through its association with and/or activation of talin and 
Rac-1 (Liebl et al., 2010; Tripathi and Zelenka, 2010). The MEF2 proteins are 
members of the MCM1-agamous-deficiens-serum response factor (MADS) family of 
transcription factors. The alternatively spliced transcripts of vertebrate MEF2 
proteins are encoded by four different genes including; MEF2A, B, C, and D and are 
regulated by posttranslational modification. They are a number of kinases that are 
responsible for up- or down-regulating the activity of Mef2 via phosphorylation. Mef2 
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exerts its regulatory effect through descending survival and death signals to the 
vasculature (Yin et al., 2012). Mef2 proteins are expressed in developing endothelial 
cells and are required for vascular survival, maintenance and development 
(Sacilotto et al., 2016). 
 
1.8.9 Cdk5 in Stroke (role and mechanisms) 
Stroke is considered as a primary cause of disability and/or death in developing 
countries. Strokes take place when the blood supply to a fraction of the brain is 
abruptly interrupted or severely reduced by, for instance, a blood clot. This 
phenomenon is referred to as an ischaemic stroke. A haemorrhagic stroke occurs 
when a blood vessel in the brain ruptures, spilling blood into the surrounding tissue, 
where the developing pressure, as well as the lack of blood supply, may cause the 
death of neurones. When the neurones within the brain no longer receive oxygen 
and nutrients from the blood, they die within a few minutes and may cause 
permanent disablement of body parts controlled by these brain regions. The matter 
is particularly problematic because brain cells once lost cannot be replaced (Caplan, 
2009). The loss of brain cells is the result of an abnormal activation of multiple brain 
cell death pathways. In contrast, angiogenesis, vascular remodelling and 
neurogenesis are all essential processes for tissue recovery (Panickar et al., 2008; 
Slevin and Krupinski, 2009). Various studies have highlighted the significance of the 
process of microvascular angiogenesis for neurone replenishment and survival, 
displaying the latter as a potential target for therapies (Slevin and Krupinski, 2009). 
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Therefore, the characterisation of novel angiogenesis signalling proteins with 
potential therapeutic benefits is essential. Many lines of evidence indicate that 
deregulation of a set of cell cycle kinases has been implicated in neuronal death 
following ischaemic insult and neurodegenerative disorders (Liebl et al., 2010; 
Takacs et al., 2010). Cdk5 and its two activators (the p35/p25 peptides) are 
regarded as key mediators in neuronal survival through the activation of 
angiogenesis (Potthoff et al., 2007; Tripathi and Zelenka, 2010; Chillakuri et al., 
2012; Yin et al., 2012). 
In the presence of various neurotoxic insults, including brain ischemia and oxidative 
stress, Cdk5 is hyperactivated with potentially fatal consequences in respect to 
neurones (Ikeda et al., 2000; Rajdev et al., 2000; Glading et al., 2002; Liebl et al., 
2010). On the other hand, lack of Cdk5 activity also leads to neuron cell death 
emphasising that appropriate control of Cdk5 activity is crucial for normal cellular 
homoeostasis. Evidence demonstrates that a crucial determinant of Cdk5 activation 
is the protein-protein interactions with its two regulatory partners p35 and p25 
(Kanungo et al., 2009). The increase in intracellular calcium in neuronal cells 
undergoing apoptosis (due to physical pressure and/or lack of blood supply) induces 
the production and release of calpain to the surrounding tissue. The activation of 
calpain has been demonstrated to increase the cleavage of p35 into p25 peptide in 
the ECs of the ruptured blood vessel. The increase in p25 was suggested to lead to 
the hyperactivation of Cdk5 (Glading et al., 2002; Liebl et al., 2010), causing cell 
death by apoptosis. 
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In an in vitro experimental model of stroke (brain microvascular endothelial cells 
subjected to oxygen-glucose deficiency), the overexpression of Cdk5-wild type in 
the endothelium significantly protected ECs against damage resulting from stroke, 
whereas a dominant negative Cdk5 (Cdk5 kinase-inactive mutant), gave little or no 
protection (Panickar et al., 2008). This may suggest a role of wild-type Cdk5 in 
promoting new vascular generation leading to increased vessel formation and 
reperfusion, as well as the restoration of the blood supply, thereby protecting 
neurones from further damage in vivo. Nonetheless, little is known about its role in 
the latter in microvascular ECs under normal conditions. However, the effect of Cdk5 
in contributing to neuronal death following ischaemia has also been evidenced, 
through different stimuli (Slevin and Krupinski, 2009). For instance, in the damaged 
areas that protrude into the peri-infracted region, the associated vessels 
overexpress Cdk5/p35 and were TUNEL-positive, indicative of EC-death of these 
microvessels (Potthoff et al., 2007). Recently, Liebl et al. reported that Cdk5 as a 
modulator of neuronal processes also regulated ECs migration and angiogenesis. 
After inhibition or knockout of Cdk5, the ECs motility and angiogenesis was blocked 
in vitro as well as in vivo, by a mechanism involving the Cdk5-Rac1 pathway (Liebl 
et al., 2010). 
The pathway for Cdk5 activation involves an upstream excitotoxic signal 
transduction cascade induced by oxygen-glucose deficiency of hypoxia at the region 
of stroke-affected tissue (Mitsios et al., 2007). Hypoxic conditions lead to excessive 
activation of the calcium-activated cytosolic proteases (calpains), which act by 
cleaving p35 to the more stable p25 peptide leading into Cdk5 hyperactivation and 
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neurones and ECs apoptosis. On the other hand, the modulation of p35 and its 
binding with Cdk5 demonstrated a contribution to cytoprotection (Shi et al., 2012; 
Barros-Miñones et al., 2013). The nuclear translocation and/or up-regulation of 
Cdk5 and p35 in neurons and ECs and the subsequent Cdk5/p35 pathway is 
regarded as a key pathophysiological determinant of ECs survival and ultimately 
outcome after infarction (Mitsios et al., 2007; Bosutti et al., 2013) as well as being 
novel potential targets for cell protection and improved tissue remodelling after 
stroke (Slevin and Krupinski, 2009; Barros-Miñones et al., 2013). The use of 
inhibitors such as Roscovitine (Timsit and Menn, 2012; Bosutti et al., 2013) has 
been shown to affect the physiological function of Cdk5 and/or the regulation of 
synaptic plasticity (i.e. calpain inhibitors) (Koumura et al., 2008). Thus the side 
effects of Roscovitine can, therefore, compromise any therapeutic efficacy (Slevin 
and Krupinski, 2009). Therefore, it is essential to identify and characterise specific 
inhibitors for the Cdk5/p25 complex formation to re-generate Cdk5/p35 (Barros-
Miñones et al., 2013) and enhance the re-vascularisation of the brain tissue after 
stroke (Slevin and Krupinski, 2009). The in-depth understanding and use of the 
neuronal cytoprotective natural small peptide (CIP-peptide) after neurotoxic stress 
may provide a therapeutic potential. CIP is a derived-p35 cleavage peptide that 
selectively targets Cdk5/p25 activity without affecting Cdk5/p35 signalling 
(Kesavapany et al., 2007). 
Cdk5 has a role in promoting synaptic plasticity (Ohshima et al., 2005), learning and 
the formation of memories (Guan et al., 2011). Furthermore, Cdk5 has been 
demonstrated to be transiently upregulated under stress conditions and was shown 
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to facilitate context-dependent fear conditioning (Fischer et al., 2003). Likewise, an 
increase in Cdk5 activity, accelerated calpain-mediated degradation of the NMDA 
receptor subtype 2B (NR2B), leading to learning deficits (Sato et al., 2008). Taken 
together these findings suggest a role of Cdk5 in promoting long-term potentiation 
(LTP) and long-term depression (LTD), with an ability to counteract changes 
induced by LTP and LTD to maintain neuronal network stability; functioning as a 
homeostatic regulator of synaptic plasticity. However, these findings were 
contradicted by Hawasli et al., highlighting a negative role for Cdk5 in learning and 
memory formation when there is an initial loss of Cdk5 resulting in enhanced LTP, 
NMDA-receptor-mediated synaptic plasticity and enhanced performance in 
hippocampal behavioural learning tasks (Hawasli et al., 2007; Shah and Lahiri, 
2014). 
 
1.9 Aims, Objectives and Hypothesis 
The aim of the study is to understand how Cdk5 regulates cell survival and 
angiogenesis in stroke. The role of the Cdk5-p35/p25 pathway in maintenance of 
the vascular bed and angiogenesis will be investigated in human brain 
microvascular endothelial cells (hBMECs) under mimicked stroke conditions. 
The objectives were, therefore: 
 To establish an effective in vitro hypoxia, that mimics a stroke, using 
hBMECs. 
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 To investigate the mechanism(s) that mediate cell attachment, spreading 
and migration and the levels of p35/p25 under hypoxia in Cdk5 over-
expressing cells. 
 Examine how tube formation, sprouting, angiogenesis and wound healing 
are affected by hypoxia and/or DAPT. 
 Examine the impact of calcium treatment on CIP expressing and Cdk5- 
over-expressing hBMECs. 
 To determine the impact of hypoxia on the expression of heat shock 
protein (HSP-70), ERK and caspase-3 in hBMECs. 
 
Hypothesis: 
The hypothesis of the current study is that Cdk5/p35 stimulates cell survival and 
angiogenesis in stroke. 
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Chapter 2 Materials and Methods 
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2.1 Materials 
 Chromatography paper (Whatman Schleicher &ScuellInternational Ltd, 
England) 
 Coverslips (Scientific laboratory supplier Ltd, SLS, UK) 
 Cryovials (Nunc Corporation, Roskilde, Denmark) 
 Eppendorf tube 0.5 ml, 1.5 ml and 2.0 ml (Nunc Corporation, Roskilde, 
Denmark) 
 Nitrocellulose membrane (Schleicher & Schuell) 
 Pipettes 0.5-10, 5-50, 50-200,100- 1000 µL (Scientific laboratory supplies 
Ltd)  
 Sterile bijous (SLS, UK) 
 Sterile plates 6-well, 24-well and 48-well (Nunc, Denmark) 
 Sterile universal containers (SLS, UK) 
 Superfrost slides (76x26) mm (Thermo Scientific, Germany) 
 Tips (white, yellow and blue) (Thermo Scientific, Germany) 
 Tissue culture plates (6-well, 12-well, 24-well, 48-well and 96-well) (Thermo 
Scientific, Germany) 
 Tissue culture flasks (T-25, T-75) (SLS, UK) 
 
2.2 Equipment 
 Autoclave (Lab Impex Research, UK) 
 Autovortex mixer SA1 (Stuart Scientific Co, UK) 
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 Axivoert fluorescence microscope (Zeiss, Oberkochen, Germany) 
 Balancer (Sartorius analytic) 
 Centrifuge (Mik20) 
 CO2 incubator (Lab Impex Research, UK) 
 Electrophoresis unit mini-Protean® 3 (Bio-Rad, USA) 
 Freezer -80C° (Juan Quality System, London, UK) 
 G-box (Syngene, UK) 
 ChemiDoc Touch Imaging System (Bio-rad Ltd, UK) 
 Ice maker (Borolab Ltd, UK) 
 Image J software analyser (Free online software) 
 Laboratory fridge (SLS, UK) 
 Laboratory pH/ temperature meter (Model AGB-75, UK) 
 Laminar flow hood tissue culture grade (Walker safety cabinet Ltd, UK). 
 Liquid nitrogen (BOC CryospeedThermolyne) 
 Magnetic stirrer hot plate (Stuart Scientific CO., UK) 
 Microscope (Nikon TMS) 
 Modular incubator chamber (Billups-rothenberginc., USA) 
 Nikon camera (Nikon Coolpix 4500) 
 Pipettes 0.5-10,5-50,50-200,100-1000 (Scientific laboratory supplies Ltd, 
SLS)  
 Power supply PS-251-2 (Sigma-Aldrich) 
 Rotating shaker (Grant-bio PS0-300) 
 Spectrophotometer (Pharmaxia Biotech). 
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 TC10™ Automated Cell Counter (Bio-Rad, USA) 
 Trans-blot SD semi-dry transfer (Bio-Rad, USA) 
 Ultra-low -80 freezer (Nuaire, USA) 
 Water-bath (Grant instrument Ltd., UK) 
 Hypoxic chamber (Grant instrument Ltd., UK) 
 
2.3 Chemicals 
 1X Tris/Borate/EDTA (TBE) buffer, (Sigma, UK)  
 2-Propanol, for molecular biology, ≥ 99% (Sigma, UK)  
 40% Acrylamide/Bis solution (Bio-Rad Laboratories, UK)  
 Ammonium persulphate (Sigma, UK)  
 *Anti-Caspase 3, Active antibody produced in rabbit polyclonal (Sigma, UK). 
 *Anti-Caspase 3 antibody produced in rabbit (Sigma, UK). 
 *Anti-Phospho-Erk1/2 (E-4) mouse monoclonal antibody (Santa Crus 
Biotechnology). 
 Bio-Rad protein assay kit (Bio-Rad Laboratories, Germany)  
 Bis (N, N’-methylene bisacrylamide) (Sigma, UK)  
 Blue wide range pre-stained protein ladder (Geneflow, UK)  
 Bovine serum albumin, BSA (Sigma, UK)  
 Bromophenol blue (Serva)  
 Caspase 3, Active antibody produced in rabbit polyclonal (Sigma, UK)  
 Distilled water (Millipore, UK)  
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 DMSO, Dimethyl sulfoxide (Sigma, UK)  
 Ethanol (absolute for molecular biology) (Sigma, UK)  
 EZ-ECL chemiluminescence detection kit for HRP (Biological industries, 
Israel)  
 FBS- Brazilian Origin (Lonza, USA)  
 Glycine (BDH, UK)  
 Hydrochloric acid (Fisher Scientific, UK)  
 Hydrogen peroxidase (Sigma, UK) 
 Hypoxia gas (Boc Gases, UK) 
 Isopropanol (Sigma, UK) 
 Matrigel™ Basement Membrane Matrix 10 ml (BD, UK)  
 Methanol (Fisher Scientific International, UK)  
 Skimmed milk (Local store, UK)  
 N, N, N’, N’- tetramethylethylenediamine (TEMED) (Sigma, UK)  
 Paraformaldehyde (Sigma, UK)  
 Phosphate Buffer Saline, PBS (Lonza, USA)  
 Phosphate Buffered Saline (Dulbecco A) tablets (Fisher Scientific, UK)  
 Phosphate Buffered Saline (Dulbecco A) tablets (Fisher Scientific, UK)  
 Polyclonal Goat Anti-mouse Immunoglobulin/Horseradish peroxidase, HRP 
(Dako, Denmark)  
 Protease inhibitor cocktail (Sigma-Aldrich, UK)  
 RIPA buffer (Sigma-Aldrich, UK)  
 Sodium chloride (Sigma-Aldrich UK)  
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 Sodium Dodecyl Sulphate, SDS (BDH, UK)  
 Sodium hydroxide (BDH, UK)  
 Tris (hydroxylmethyl) methylamine (BDH, UK)  
 Trypsin-EDTA 1X (Lonza, USA)  
 Tween® 20 (Sigma, UK).  
 
2.4 Required Buffers 
2.4.1 Blocking buffer 
1% (w/v) Bovine serum albumin (BSA) in TBS-Tween or 4% (w/v) of non-fat dry milk 
in TBS-Tween. TBS-Tween must be stored in the refrigerator at PH7.4  
 
2.4.2 Electrode buffer 
12.02 g Tris-base, 4g Sodium Dodecyl Sulphate (SDS), 57.68g glycine made up 
with 2 L of dH2O. 
 
2.4.3 Milk (required for the secondary antibodies) 
5% (w/v) skimmed milk powder in TBS-Tween with pH adjusted to 7.4. Must be 
made fresh for each use. 
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2.4.4 Sample buffer (pH 6.8) 
Tris-base 1.51 g, 20 ml glycerol mixed with 20 ml of d H2O. Then add 4g of SDS, 
3.6 ml of mercaptoethanol and 0.004 g bromophenol blue, and made up to 100 ml 
with dH2O. 
 
2.4.5 Separating buffer (pH 8.8) 
Tris-base 36.3 g, and SDS 0.8 g dissolved in 250 ml of dH2O. 
 
2.4.6 Stacking buffer (pH 6.8) 
Tris-base 15 g and SDS 1 g dissolved in 250 dH2O. 
 
2.4.7 Towbin buffer 
Tris-base 1.51 g, glycine 7.2 g, SDS 0.167 g and 75 ml methanol then this 
combination was made up to 500 ml with dH2O. 
 
2.4.8 TBS-Tween buffer 
Tris-buffered saline and Tween-20 (TBS-Tween pH 7.4): Tris-base 2.422 g, NaCl 
16.36 g and 2 ml of Tween 20 mixed up to 2 L with dH2O. 
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2.4.9 RIPA buffer 
20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton 
X-100, 1% (w/v) sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM 
Na3VO4, 1 mM β-glycerophosphate, 1 μg/ml leupeptin, 1 mM PMSF. 
 
2.5 Cell Culture Medium 
Endothelial basal medium-2 (EBM-2) supplemented with 2% (v/v) foetal bovine 
serum  (FBS), Hydrocortisone, recombinant human Fibroblast Growth Factor B 
(rhFGF-B), recombinant human Vascular Endothelial Growth Factor (rhVEGF), 
Recombinant long Receptor Insulin-like Growth Factor-1(R3 IGF-1), Ascorbic Acid, 
recombinant human Epidermal Growth Factor (rhEGF) and  Gentamicin sulphate 
Amphotericin-B (GA-100), were made up according to the supplier’s 
recommendations. 
 
2.6 Methods 
2.6.1 Cell Line and Cell Clones 
2.6.1.1 Human brain microvascular endothelial cell line 
The Immortalised human brain microvascular endothelial cell line (hBMECs) 
(Haarmann et al., 2010) was used as the cell model for this study, which was kindly 
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provided by Prof Babette Weksler (Division of Haematology and Medical Oncology, 
Weill Medical College of Cornell University, New York). 
All cell culture methods were carried out under sterile conditions. 
 
2.6.1.2 Transfecting hBMEC and Selecting Cell Clones  
Stable hBMECs overexpressing Cdk5 transfectants (OVCdk5) were generated by 
stable transfection of wild-type human Cdk5, (Cdk5-wt), which were obtained from 
pcDNA3-cdk5GFP expression vectors (Addgene, USA), using TransIT-2020 as 
transfection reagent (Mirus Bio LLC, Madison, USA). Cdk5 inhibitory peptide (CIP) 
was transferred with pcDNA-GFP-CIP. Non-transfected hBMECs was used as a 
control.  
For the transfection, 2.5 µg of plasmids + 7.5 µL TransIT-2020 were added to 260 
µL of EBM-2 medium containing 500 µg/ml of geneticin (G418, Invitrogen Life 
Science, UK) was used as a selective medium and incubated for 30 min at RT prior 
to being used. When the cell confluence reached about 90%, the DNA complex was 
added to cells and incubated for 24 hours. 
For instance, the transfected cells were seeded in EGM-2 medium containing 500 
µg/ml G418. After one week, G418 was changed to 300 µg/ml. Then after another 
week, G418 was reduced to 200 µg/ml. About one month after seeding, the drug 
medium was changed to normal EBM-2 medium. Transfection efficiency was 
defined by the presence of GFP fluorescence and Cdk5 protein levels in cells. 
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2.6.1.3 CIP Cloning and Stable Transfections 
A modified EGFP-IRES vector containing the CIP sequence (Kesavapany et al., 
2007), (pLV-CIP plasmids), was a kind gift from Prof Sashi Kesavapany, National 
University of Singapore. CIP peptide is comprised of 126 residues of p35 protein 
(accession number: AAH26347.1) spanning from aa 154 to aa 279. CIP-PCR 
products from pLV-CIPplasmid were obtained by polymerase chain reaction (PCR) 
(forward primer, TTA GGA TCC TTG CCT GGG TGA GTT TC and reverse primer, 
GTC GGA TCC TCA TGG GTC GGC ATT TAT C) and digested with Bacillus 
amyloliquefaciens (BamHI) (Invitrogen, UK) were then inserted by ligation into the 
pcDNA3-GFP expression vector. After positive cloning in DH5α, purified pcDNA3-
CIP-GFP vectors were stably introduced by transfection into hBMECs using 
TransIT-2020 transfection reagent (Mirus Bio LLC, Madison, USA). EGM-2 medium 
containing 500 µg/ml G418 (Invitrogen Life Science, UK), was used as a selective 
media. 
Positive hBMECs clones were detected by GFP fluorescent signals and by the level 
of CIP mRNA by RT-PCR. 18S rRNA (accession number: NM - 022551.2) was used 
as a housekeeping gene (forward primer, TAG AGG GAC AAG TGG CGT TC and 
reverse primer, TGT ACA AAG GGC AGG GACT T). Resistant clones were 
detected by GFP fluorescent signals under fluorescence microscopy, and the level 
of CIP mRNA confirmed by RT-PCR. (This work was done by Dr Jie Qi, School of 
Healthcare Science, Manchester Metropolitan University). 
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2.6.2 Thawing Cells 
The thawing process was done in the quickest possible time to ensure that a high 
quantity of cells survived in the stressful procedure. When required, the cryovial 
containing frozen cells was taken out from liquid nitrogen and immediately defrosted 
by gently swirling in a water bath at 37°C. The pressure inside the vial was released 
inside a Laminar flow hood and the frozen cells were defrosted at 37°C water bath. 
Once defrosted, the cryovial was sprayed with 70% (v/v) ethanol and the contents 
were transferred into a flask [pre-coated with 0.1% (v/v) Poly-L-lysine solution] and 
maintained in a humidified 5% CO2 atmosphere at 37°C. The medium was then 
replaced with fresh complete cell growth medium after 24 hours. 
 
2.6.3 Cell Culture and Sub-Culture 
Human brain microvascular endothelial cell line (hBMECs), CDK5 inhibitory 
peptides (CIP) and overexpressing Cdk5 transfected hBMECs (OVCdk5) were 
grown in EBM-2 medium supplemented with growth factors and 2% (v/v) FBS. Cells 
were seeded into T-25 flasks pre-coated with 0.1% (v/v) Poly-L-lysine solution and 
maintained in a dH2O humidified 5% CO2 atmosphere at 37°C. The cell growth 
medium was changed every three days, and when cells reached confluence, they 
were detached under the enzymatic activity of trypsin. Briefly, cell growth medium 
was discarded, and the cells were washed three times with 5-10 ml of warm PBS. 
Then, 2 ml of pre-warmed (1×) trypsin/EDTA at 37°C was added to cover the entire 
surface of the cell monolayers, and incubated for 5 mins in order to detach the cells 
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from the flasks. Following that, the action of the trypsin was blocked by adding an 
equal amount of fresh cell growth medium. After that, the cells in the suspension 
were collected in a universal tube and centrifuged at 300×g for 5 mins. The 
supernatant was discarded, and the cell pellet was re-suspended in fresh complete 
medium. The cells were seeded into fresh flasks or plates pre-coated with 0.1% (v/v) 
poly-L-lysine solution for further experimentation. Throughout the study, the cells 
used in all experiments were between passages 8 and 18. Cells were passaged 
when they had reached about 90% confluence. 
 
2.6.4 Preparation of Freezing Medium 
The freezing medium was prepared to contain 10% (v/v) dimethyl sulphoxide 
(DMSO) in FBS. Briefly, 1 ml of DMSO in 9 ml of cold FBS was mixed and kept at -
20°C until use. The fresh freezing medium was prepared or defrosted shortly before 
use. 
 
2.6.5 Freezing Cells 
The trypsinised cells taken from the flask were centrifuged at 300×g for 5 minutes; 
the supernatant was then removed, and the cell pellet was re-suspended in 250 µL 
of complete medium with the addition of 750 µL of 10% (v/v) DMSO (freezing 
medium). One ml of the medium containing approximately 2.5×106 of cells was kept 
in a 1.5ml cryovial labelled with the cell passage, number and date. Cryovials 
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containing cells were kept at -20°C for 30 minutes. then the cryovial was transferred 
into a -80°C freezer overnight. After 24 hours, the cryovial was transferred to liquid 
nitrogen (-190°C) and the location was recorded. 
 
2.6.6 Cell Counting 
Following trypsinisation and centrifugation, 20 µL of the cell suspension was mixed 
with 20 µL of trypan blue and was then transferred into a haemocytometer chamber 
with 1×1×0.1 mm dimensions (covered with a coverslip) and visualised under a 
microscope with a 10× objective. The cell number was counted per each square of 
the haemocytometer using the formula illustrated in Figure 2.1 (number 1-5 squares) 
taking into consideration the dilution factor. 
 
 
 
 
Cell number per mL = the 
average count per square × the 
dilution factor × 104. 
 
Figure 2-1 The haemocytometer for counting cells with the equation used 
for the cell count 
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2.7 Angiogenesis Assays 
2.7.1 Cell Migration (Wound Healing) 
hBMECs, CIP expressing cells and OVCdk5 were seeded respectively at a 
concentration of 2 × 10⁵ cells/ml in 500 µL of complete medium in each well of a 
poly-L-lysine pre-coated 24-well plates. After 24 hours of incubation at 37°C in 5% 
CO2, the medium was replaced with serum poor medium [SPM, basal medium 
containing 0.5% (v/v) FBS]. Each well of the 24-well plates was washed with warm 
PBS three times and a wound was made using a sterile pipette tip. The wells then 
were washed carefully with warm PBS three times to remove any floating cells.  
Then calpain (0.1 μM) was added, and SPM [0.5% (v/v) FBS EBM-2] was applied 
to the cells, then the cells were incubated under hypoxic [1% (v/v) O2] and normoxic 
conditions respectively for 24 hours. 
Normal hBMECs, CIP expressing cells and OVCdk5 were incubated with FGF-2 (25 
ng/ml) and γ-secretase (DAPT, inhibitor, at 10 mΜ) where appropriate. After 24 
hours incubation, 50 µL of 4% (w/v) paraformaldehyde (PFA) was added to each 
well to fix the cells at room temperature (RT) for 15 mins. The medium was then 
removed, and the wells were washed with PBS. 100 µL of 100% ethanol was added 
to the cells and left for 5 mins. Then the ethanol was removed, and the wells were 
left to dry before staining the cells with methylene blue for 5 mins. The stain was 
removed, and the wells were washed with distilled water (dH2O). Finally, the cells 
were examined under the microscope and pictures were taken. In this experiment, 
cells were treated in triplicate for each experimental condition and pictures of five 
areas of each well were taken. The picture analysis was performed using Image-J. 
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2.7.2 Tube-like Structure Formation in Matrigel™ 
The 96-well plate was coated with 50 μl of Matrigel™ and then put in an incubator 
at 37°C for 1 hour.  hBMECs, CIP expressing cells and OVCdk5 (8×103 cells) were 
mixed respectively in 50μL of medium with various of conditions, and with or without 
DAPT inhibitor (10µg/ml), FGF-2 (25ng/ml). After 24 hours incubation, 4% (w/v) PFA 
was added to fix the endothelial tube-like structures in the well. Under an optical 
microscope, closed areas surrounded by endothelial tube-like structures were 
counted in 3-5 areas from each well. 
 
2.7.3 Spheroid Sprouting Assay 
After the initial trypsinisation stage, cells (6×105 cells/ml suspended in EBM-2 
medium) were added to non-adhesive 96-well Greiner® plates (Sigma, UK) for 
suspension culture. Firstly, 6 ml of methylcellulose was made up with 30 ml of EBM-
2 medium, from this 15 ml were added to 250 µL of the initial cell volume. The cells 
(150 µL/well) were then added to the 96-well plates and incubated in a 5% CO2 
incubator at 37 ºC for 24 hours. 
In a separate bijou, 1.33 ml of collagen gel solution at (2 μg/ml) was added to 920 
µL of EBM-2 medium and kept on ice. The spheroids were collected, added to 15 
ml tubes and centrifuged at 400×g for 3 mins. When a clear pellet was distinguished, 
the supernatant was removed, and 250 μL methylcellulose gel was added. Before 
adding the spheroids in the 24-well plate, the collagen solution was neutralised by 
adding 150 µL 0.1 N NaOH. If the 0.1 N NaOH had been added early, the collagen 
54 
gel solution would have polymerised. The solution turned pink once resuspended. 
The spheroids were then added to the 24-well plates at 500 µL/well. Before adding 
the spheroids to the 24-well plates ensure the sterile tip was cut slightly from the tip 
to avoid damaging them. They were incubated at 37ºC, in 5% CO2. After 24 hours, 
the spheroids were fixed with 4% (w/v) PFA for 15 min at room temperature and 
pictures were taken. Sprouting occurred from the spheroid core, and the sprout 
length was estimated with the software Image-J using five spheroids with similar 
sizes of the core of spheroid. 
 
2.8 Hypoxia Studies 
Hypoxia is defined as the reduction or lack of oxygen in organs, tissues, or cells. For 
an in vitro mimicked stroke condition, a hypoxia chamber was used in this study to 
provide a flow with different gas compositions as compared to normal atmospheric 
flow. The cell culture plates were placed in the hypoxic chamber (see appendices 
7.3); also, a dish containing sterile water was placed in the chamber to provide 
adequate humidification of the cultures. The chamber was sealed airtight. All oxygen 
present in the chamber was removed by opening the gas tank at a flow rate of 20 
litres per minute for about 5 mins feeling gas flowed out from another tube, which 
was linking in the chamber. Then quickly sealed off the out-tube with a clamp, then 
turned the gas flow down to 5 litres per min, and after this quickly turned off the gas 
flow and completely closed the chamber by closing both white clamps. The chamber 
was then put in a conventional incubator for the desired period. 
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2.9 Propidium iodide (PI) Staining 
To study the protective effect of Cdk5 on ECs in hypoxia, glass coverslips were 
bathed in 100% ethanol for 10 - 20 min and left to air dry in a sterile environment. 
The coverslips were put in a 24-well plate and pre-coated with 500 μL of 0.1% (v/v) 
poly-L-lysine solution. After 10 min incubation, the coverslips were washed with PBS 
and the cells were grown in complete growth medium at a cell (hBMECs) 
concentration of 5×10⁴ cells/ml. After a 24-hour incubation, the completed growth 
medium was removed and replaced with SPM containing 0.5% FBS and incubated 
for 24 hours in hypoxic (1% O2) and normoxic conditions respectively. OVCdk5 and 
CIP expressing cells were also incubated in hypoxic conditions for 24 hours. One 
hour before the termination of the experiment, propidium iodide (PI, 10μg/ml) was 
added to each well as an indicator of DNA damage without removing the medium. 
After 1 hour incubation, the cells were washed three times with PBS, and one drop 
of Vectashield mounting medium with DAPI reagent was added on frosted glass 
slides. An average of three fields at ×40 of magnification was photographed per 
coverslip by using an Axiovert fluorescence microscope (Zeiss). 
 
2.10 Protein Extraction 
hBMECs, CIP expressing cells and OVCdk5 (8×10⁵ cells/ml, 2 ml) were seeded 
respectively in complete medium in a 6-well plate. After 48 hour incubation, the 
medium was replaced with SPM containing 0.5% (v/v) FBS. Various conditions were 
applied to each well in addition to untreated cells, and then the cells were incubated 
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for 24 hours. Afterwards, the cells were washed with cold PBS and gently lysed on 
ice in 200 μL of ice-cold homogenised lysis (RIPA) buffer, with a protease inhibitor 
and a phosphatase inhibitor, pH 7.2. Then the cells were scraped, the lysate proteins 
were collected, and transferred into 0.5 ml microcentrifuge tubes and incubated on 
ice for 20 mins whilst being vortex mixed every 2 mins to make sure that the lysates 
were mixed properly. After that, the cell lysates were sonicated three times. The 
proteins were stored at -80°C until use. 
 
2.11 Protein Estimation 
The protein concentration was determined using the Bio-Rad protein assay. Briefly, 
BSA was used at 1mg/ml as a standard protein, and 10 μL of protein lysate was 
added and completed with 90 μL of dH2O in a bijou tube. After that, 2 ml of Bio-Rad 
protein assay reagent (1:4 dilution) was added into each bijou tube. The absorbance 
of each sample was measured with a spectrophotometer at 595 nm. 
The data outlining the reading of each protein sample and the standard curve 
required for protein estimation are shown below (Figure 2.2). 
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Table 2.1: The volume of BSA, dH2O and Bio-Rad required to establish the 
standard curve. 
 BSA Standard (μg)  
BSA volume added 
(1μg/µl) Volume of dH2O (µl) 
Volume of diluted 
BioRad reagent (ml) 
 0  0 100 2 
 5  5 95 2 
 10  10 90 2 
 20  20 80 2 
 40  40 60 2 
 
 
Figure 2-2 Standard curve for protein estimation 
Absorbance of BSA (in µg) at 595 nm 
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2.12 Western Blotting 
The acrylamide gel (12%) was prepared by mixing 3.3 ml of 40% bis-acrylamide 
with 4.2 ml distilled water (dH2O) and 2.5 ml separating buffer in a universal tube. 
100 µL of 10% (w/v) ammonium persulphate (APS) solution was added followed by 
10 µL N, N, N’, N’- tetramethylethylenediamine (TEMED). Few drops of isopropanol 
were added on top of the gel to remove the air bubbles and straight the surface of 
the gel, and the gel was left to polymerise for 20 mins. The isopropanol was removed 
after the gel polymerised and rinsed with dH2O. dH2O was removed by filter paper 
and then the stacking gel solution was prepared in a second universal tube by 
combining 1.45 ml of 40% bis-acrylamide with 6.1 ml dH2O, and 2.5 ml stacking 
buffer. As before, 100 µL APS was added followed by 10 µL TEMED and the 
stacking gel was left to polymerise for a minimum of 20 mins. Slowly the combs, 
clamps, and gaskets were then removed taking care not to damage the wells and 
the gel plates were inserted into the electrophoresis chamber. The chamber was 
subsequently filled with electrode buffer [25 mM Tris, 192 mM glycine, 0.1% (v/v) 
SDS, pH 8.3]. A total of 400 ml electrode buffer was used to fill the tank, in the space 
between the two sets of glass plates. Take samples, sample buffers and molecular 
weight marker out of the freezer and defrost on ice. Equal measures of protein 
sample and sample buffer were mixed in an Eppendorf tube; the mixed samples 
were placed in boiling water for 15 mins. Molecular weight marker (5 µL) and the 
protein samples were gently loaded. Total protein (30 µg) was loaded into each well. 
Samples were separated by SDS-PAGE (12%) for~45 min at 65 V (when samples 
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were in the stacking gel) and switched to 200 V for separation until the dye, 
bromophenol blue, reached the bottom of the separation gel.  
Table 2.2: Preparation of separating gel 
Material Volume 
ddH2O 4.2 ml 
40% Acrylamide 3.3 ml 
Separating buffer* 2.5 ml 
10% APS 100 µL 
TEMED 10 µL 
*Preparation method as described above with a total volume of 10.11ml. 
 
Table 2.3: Preparation of stacking gel 
Material Volume 
ddH2O 6.1 ml 
40% Acrylamide 1.4 ml 
Stacking buffer* 2.5 ml 
10% APS 100 µL 
TEMED 10 µL 
 
* Preparation of the stacking gel as described as above with a total volume of 
10.11ml. 
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2.12.1  Blotting 
The nitrocellulose membranes (NCM) and 6 pieces of chromatography paper were 
soaked for 2 mins in Towbin buffer. The stacking gel was removed from the 
separating gel and discarded. The separating gel was sandwiched and assembled 
in an electro-blotter for each gel as follows: three pieces of blotting 
paper/NCM/gel/three pieces of blotting paper. Any air bubbles within the 
sandwiches were removed by rolling a clean 5 ml tip over the sandwich. Proteins 
were transferred onto the membrane at 45 mA per gel for one hour. 
 
2.12.2  Blocking 
Membranes were blocked with 1% (w/v) BSA in Tris-buffered saline (TBS) and 
Tween-20 buffer (TBS-T) for 1 hour at room temperature (RT) on a rotating shaker. 
The 1% (w/v) BSA was discarded, and the membranes were incubated separately 
in 10 ml of primary antibody solution (1:1000 dilution) at 4°C overnight on a rotating 
shaker. The following day, primary antibody solutions were transferred into labelled 
universal tubes and sodium azide was added to a final concentration of 0.02% (w/v) 
to prevent microbial contamination. The primary antibodies were then kept at 4°C 
and were used for up to one week. The membranes were washed five times with 
TBS-T for 10 min each at RT on a rotating shaker then were incubated for 1 hour at 
RT in 10 ml of goat anti-rabbit or rabbit anti-mouse horseradish peroxidase-
conjugated (HRP) secondary antibody diluted in TBS-T containing 5% (w/v) 
skimmed milk powder (1:2000). After incubation, the secondary antibody solutions 
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were discarded, and the membranes were washed five times with TBS-T for 10 min 
each at RT on a rotating shaker. 
 
2.12.3  Developing and Data Analysis 
In a dark room, the membranes were immersed in enhanced chemiluminescence 
(ECL) solution. Chemiluminescence is a chemical reaction that generates energy in 
the form of light and fades over time. To prepare the ECL solution, an equal volume 
of solution-A and solution-B were mixed and put on the membrane in the darkroom 
for one minute, the excess reagent was then drained off, and the membranes were 
quickly wrapped in cellophane films and kept in a box. Then the membranes were 
taken to the G-Box or the ChemiDoc Touch Imaging System and were detected as 
chemiluminescent samples. The intensities of the bands on the membranes were 
quantified by Image-J analysis software. Day to day variations in luminescence 
could arise due to protein degradation or experimental errors. Therefore, loading 
controls were essential for proper interpretation of the Western blots and were used 
to normalise the levels of protein detected by confirming that the protein loading was 
the same across the gel. The expression levels of the loading control should not 
vary between the different sample lanes. The results were semi-quantitative and 
compared to the control. α-Tubulin was used as a loading control. 
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2.13 Confocal and Fluorescence Microscopical Analysis 
Glass coverslips were bathed in 100% ethanol for 10-20 min and left to air dry in a 
sterile environment. The coverslips were put in a 24-well plate and pre-coated with 
500 μL of 0.1 % (v/v) poly-L-lysine solution. After 30 min incubation, the coverslips 
were washed with PBS and the hBMECs were seeded in complete EBM-2 (2% FBS 
plus growth factors) medium. After fixing with 4% (w/v) PFA in PBS, cells were 
washed with PBS and permeabilised with 0.1% (v/v) Triton X-100  in PBS. After 
blocking with 1% (w/v) BSA in PBS incubations with primary antibodies against 
selected proteins were performed with conditions as recommended by the 
manufacturers, overnight at 4°C. Secondary antibodies Alexa Fluor 488 goat anti-
rabbit IgG, Alexa Fluor 488 goat anti-mouse IgG, Alexa Fluor 568 anti-rabbit and 
Alexa Fluor 460 donkey anti-goat (Molecular Probes/Invitrogen) were incubated with 
conditions as recommended by the manufacturer. Rhodamine-phalloidin (Molecular 
Probes/Invitrogen) was used to stain filamentous actin (F-actin). Nuclei were stained 
with Hoechst 33258 solution (Sigma, UK). The coverslips were incubated for 2 hours 
at room temperature in the dark. The secondary antibodies were removed, and the 
coverslips were washed 5 times for 5 mins each with PBS in the dark. To mount 
coverslips, the edge was blotted on tissue paper to dry off excess liquid and cell side 
was placed down on the drop of mounting media (VECTASHIELD Mounting Medium 
with DAPI) on a glass slide. The coverslip was stabilised on a slide using nail polish 
and left to dry overnight before viewing. The images were captured using Axivoert 
fluorescence microscope. Samples without primary antibodies were used as 
negative controls. Confocal microscopy was performed with a Leica TCS SPE1000 
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system and the accompanying Leica Application Suite Advanced Fluorescence 
(LAS AF) software (Leica Microsystems Ltd, Milton Keynes, Bucks, UK). Images 
were acquired at 1024x1024 pixel resolution. Cells were pre-treated with roscovitine 
(50 μM) for 24 hours or the appropriate vehicle (DMSO) and then seeded on the 
plates. The signal of autofluorescence was tested, including a negative control 
antibody (IgG) staining, as well. In this experiment, cells were treated in triplicate for 
each experimental condition and pictures of five areas of each well were taken. 
 
2.14 Statistical analysis 
Statistical analysis was made by using the Microsoft Excel 2013 program. The 
results of each experiment determined as the mean ± standard deviation. Data 
shown were analysed for significance using Two-Way ANOVA test. Differences with 
p values ≤0.05 were considered statistically significant. Each experiment was 
repeated at least three times. 
Statistical difference between more than two groups was determined using Two-
way ANOVA and Bonferroni multiple comparison tests. Statistical significance was 
set at p<0.05. 
Two-Way ANOVA test was used to assess the effects of various types of treatment 
on a different type of cells and to assess the interaction between treatments (FGF-
2, DAPT, FGF-2 + DAPT) and type of cells (hBMEC, CIP and OVCdk5). 
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Western blot was repeated at least twice but there was no statistical analysis was 
performed here. 
Statistical analysis and significance of data were determined using graph pad prism 
version (5). Graph pad software, San Diego, California, USA, www.graphpad.com. 
No statistical analysis on Western blotting – too variable from one experiment to 
another.  
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Chapter 3 Results 
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3.1 The Transfection and Selection of Stable Expression Cell Clones 
3.1.1 GFP-fluorescence Detection of CDK5 Inhibitor Peptide (CIP) 
Before all the experiments, hBMEC cell lines were checked to confirm the 
transfection of CDK5 inhibitor peptide (CIP) by the expression of Green Fluorescent 
Protein (GFP) (Figure 3.1A), and that there were no fluorescent signals in hBMEC 
normal control cells (Figure 3.1B). 
  
             A: CIP     B: hBMECs 
Figure 3-1 Expression of GFP fluorescent marker in CIP-17 clones 
transfected with pcDNA-GFP 
GFP Fluorescence images showing the successful transfection of CIP in stable hBMEC 
transfectants (A). There was no fluorescence in hBMEC normal control cells (B). 
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3.1.2 GFP-fluorescence Detection on OVCdk5 Transfectants 
This was done to confirm that the transfection of the overexpressed CDK5 kinase 
(OVCdk5) in stable hBMEC transfectants was successful (Figure 3.2 A), but there 
was no fluorescence signal in hBMEC normal control cells (Figure 3.2 B). 
  
                      A: OVCdk5     B: hBMECs control 
Figure 3-2 Expression of GFP marker in overexpressed Cdk5 clones 
transfected with pcDNA-GFP 
GFP-fluorescence images shows the transfection of Cdk5 clones in hBMECs.  
This experiment was performed to make sure that Cdk5 was expressed by stable 
OVCdk5 transfected hBMEC. Image (A) shows Cdk5 was expressed in OVCdk5-
transfected hBMEC, and there are none fluorescence signals in normal hBMEC (B). 
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3.2 Cell Culture 
3.2.1 Introduction 
Endothelial cells (ECs) normally undergo angiogenesis that includes migration and 
tube formation. Our aim was to investigate whether this property is altered under 
hypoxic conditions. 
 
3.2.2 Results 
Hypoxia almost completely inhibited in vitro angiogenesis in hBMECs, as seen by 
the reduction in cell migration from scratched monolayer tubule-like structure 
formation and/or cell sprouting. Our study demonstrates that Cdk5 activation, 
through its major substrate p35, provides a key trigger for the initiation and 
maintenance of in vitro brain EC angiogenesis and that this interaction and signalling 
cascade are crucial for ensuring correct cytoskeletal organisation/dynamics. Our 
results also show that by introducing a natural inhibitor of the p25/Cdk5 complex 
formation, the CIP peptide (Kesavapany et al., 2007), we were able to alter the 
balance of p25/p35-Cdk5 signalling in favour of p35, and concomitantly significantly 
increase in vitro brain EC angiogenesis during normoxia. Most importantly, this also 
promoted cell survival and capillarisation in hypoxic conditions (Bosutti et al., 2013). 
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3.2.2.1 Hypoxia-Induced Cell-Damaging Effects in hBMECs 
Propidium Iodide (PI) is usually excluded from surviving cells and used to identify 
dead cells in a population. Cells were observed using fluorescence microscopy with 
two filters, DAPI fluorescent filter and rhodamine filter with × 40 magnification. 
hBMECs considered apoptotic will display signs of apoptosis such as condensation 
of nuclear materials, incorporation of PI stain (colour in red, when PI staining) in the 
nucleus, disruption of cell cytoplasm and shrinkage of the cells. The normal cells 
appeared regular with round clear blue nuclei. 
The representative results are shown in Figure 3.3 (image) and Figure 3.4 (graph). 
Hypoxia-induced cell-damaging effects in hBMECs showed increased PI stained 
nuclear inclusion (the arrows indicate the nuclei stained by PI, in red). 
 
Figure 3-3 PI staining and the presence of PI in nucleus representative 
damage to the cell exposed to hypoxia 
In this experiment, the efficiency of hypoxia was evidenced by the increased nuclear 
inclusion of PI. Surviving cells remained blue, but others became apoptotic and were 
stained red by PI (arrows, B). 
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Figure 3-4 Bar chart indicates the significant difference from the normoxia 
control and hypoxia-induced cell-damaging in hBMECs 
The percentage of hBMECs stained by PI was increased in hypoxia compared to normoxia. 
The bars represent the standard deviation.  
PI staining showing a *significant increase (80%) in the number of PI-stained cells 
in hypoxia vs. normoxia, p <0.05. The experiments were performed in triplicate wells 
and repeated three times. 
 
3.2.2.2 Cell Angiogenesis Assay 
Previous work from our laboratory showed that Cdk5 can promote angiogenesis, 
hence our aim was to investigate the role of Cdk5 in promoting angiogenesis in 
normal versus stroke mimicking conditions (hypoxia) as well as the role of CIP in 
71 
reversing cellular apoptosis and allowing angiogenesis under hypoxia. To fulfil this 
aim, a series of experiments was conducted related to wound healing and tube 
formation in hBMECs, CIP-expressing cells and OVCdk5. 
 
3.2.2.2.1 Cell Migration Assay 
The scratch wound methods were applied to the hBMECs, Cdk5 kinase inhibitory 
peptide (CIP) and (OVCdk5) transfectants to compare the effects hypoxia. The 
images were taken using a camera under the microscope (Figure 3.5). 
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Figure 3-5 Cell migration assay on CIP- expressing cells and OVCdk5 
1: hBMECs (normoxia), 2: CIP expressing cells (normoxia), 3: OVCdk5 (normoxia), 4: 
hBMECs (hypoxia), 5: CIP expressing cells (hypoxia) and 6: OVCdk5 (hypoxia). 
Phase contrast images showed the impact of Cdk5 deregulation on cell migration under 
hypoxic conditions (1% O2, 24 hours) compared to the normoxic condition (three views per 
well). 
Cell migration assays were performed in hypoxia and normoxia, in hBMECs, CIP-
expressing cells and overexpressing Cdk5 (OVCdk5). Hypoxia inhibited hBMECs 
migration, as seen by the reduction (number of cells in the wound area), Figure 3.5 
(4, 6), but there were significantly more of cells in CIP-expressing cells, Figure 3.5 
(5). Experiments were performed in triplicate wells and were repeated three times.  
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Figure 3-6. The effect of hypoxia on cell migration. 
The effect of 24 hours incubation in hypoxia on the migration of hMBECs, CIP-expressing 
cells and OVCdk5 cells.  
A * significant increase in the number of migrated CIP-expression cells in hypoxia 
vs. normoxia, p <0.05. Two-Way ANOVA test was used to assess the effects of 
hypoxia and normoxia on a different type of cells. The experiments were performed 
in triplicate wells and repeated three times. 
  
 
 3.2.2.2.2 Effects of DAPT on Cell Migration 
The Cdk5 inhibition assay was performed during 24 hours of Cdk5 inhibition (cells 
treated with DAPT at 10µM), in normal hBMECs and OVCdk5. DAPT inhibited 
hBMECs migration, as seen by the reduction (in the number of cells in the wound 
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area, Figure 3.7 (3). DAPT also inhibited cell migration in OVCdk5, as seen by the 
number of cells that migrated to the wound area, Figure 3.7 (7). There was a large 
number of migrated cells (incubated with FGF-2) in the wounded area, Figure 3.7 
(2, 6). 
 
Figure 3-7 Effects of Cdk5 inhibition on cell migration 
Top row-1: hBMECs control, 2: hBMECs positive control (FGF-2 25ng/ml), 3: hBMECs 
treated with DAPT (10µM) and 4: hBMECs treated with DAPT (10µM) plus FGF-2 (25ng/ml). 
In the middle- 5: CIP, 6: FGF2, 7: CIP + DAPT, 8: CIP+FGF2+DAPT. Lower panel – 9: 
OVCdk5 control, 10: OVCdk5 treated with FGF-2 25ng/ml, 11: OVCdk5 treated with DAPT 
(10µM) and 12: OVCdk5 treated with DAPT (10µM) together with FGF-2 (25ng/ml). The 
experiments were performed in triplicate wells and repeated three times. 
 
Phase contrast images showing the impact of DAPT (Cdk5 inhibitor) on cell 
migration compared to normal hBMECs. DAPT inhibits cell migration, as seen by 
the number of cells migrated into the wound area (Figure 3.7-5). It can be seen from 
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the images that more cells had migrated into the wound area (both of the hBMECs 
and the OVCdk5 than the cells treated with DAPT. DAPT inhibits the effects of Cdk5 
on cell activation. However, CIP did not produce the same level of response 
compared to OVCdk5, the reason could be the biological effect of CIP-expression 
is blocking apoptosis through Cdk5/p25 signalling pathway.  
 
Figure 3-8 The effect of DAPT on cell migration. 
The effect of Cdk5 inhibitor (DAPT) on hBMECs, CIP-expressing cells and OVCdk5 cell 
migration. After 24 hours incubation in hypoxia, DAPT is the same concentration (10µM). 
A *significant effect of DAPT treatments was observed on OVCdk5 cells compared 
to hBMECs, p<0.05. Two-Way ANOVA test was used to assess the effects of 
various types of treatment on a different type of cells and to assess the interaction 
between treatments (FGF-2, DAPT, FGF-2 + DAPT) and type of cells (hBMEC, CIP 
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and OVCdk5). The experiments were performed in triplicate wells and repeated 
three times. 
 
3.2.2.2.2 The Effects of Calpain on Cell Migration Assay 
The effect of calpain on hBMEC migration assay was analysed after 24 hours, 
incubation under hypoxic condition compared to the normal condition. The images 
show significantly more cells in the wounded area under normal conditions (1 top 
left) than the cells treated with calpain (2 top right). There are decreased numbers 
of migrated cells (3 lower row left) compared to cells in hypoxia (4 lower row right). 
 
Figure 3-9 The effect of calpain on hBMECs migration assay 
1: hBMECs (normoxia), 2: hBMECs treated with calpain (10µg/ml, normoxia), 3: hBMECs 
(hypoxia) and 4: hBMECs treated with calpain (10µg/ml, hypoxia). 
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Assays were performed over 24 hours, incubation, and the images were taken using 
a camera under the microscope (Figure 3.9). 
 
 
Figure 3-10 Bar chart representing the cell migrated numbers  
The effect of 24 hours incubation calpain treatment on hBMEC, -cell migration compared to 
untreated cells. 
 
Two-Way ANOVA test was used to assess the effects of hypoxia and normoxia on 
a different type of cells and to assess the interaction between them. It showed a 
****significant decrease in the number of treated migrated cells (p<0.0001). 
 
 
78 
3.2.2.2.3 Effect of Hypoxia on Tube Formation 
In order to investigate the consequences of hypoxia and Cdk5 deregulation on 
hBMECs tube formation, the assays were performed during 24 hours of the hypoxic 
and normoxic-control conditions, in hBMEC, CIP-expressing cells and OVCdk5. 
Hypoxia almost completely inhibited hBMECs forming tube-like structures, Figure 
3.11 (4). The OVCdk5 and the CIP-expressing cells were still able to migrate to form 
new capillary structures under hypoxic condition, Figure 3.11 (5, 6). 
 
Figure 3-11 Phase contrast images showing the impact of Cdk5 deregulation 
on cell capillary tube formation under hypoxia (1% O2, 24 hours) compared to 
normoxic conditions 
1: hBMECs (normoxia), 2: CIP-expressing cells (normoxia), 3: OVCdk5 (normoxia), 4: 
hBMECs (hypoxia), 5: CIP-expressing cells (hypoxia) and 6: OVCdk5 (hypoxia). 
Phase contrast images showing the impact of hypoxia and Cdk5 deregulation on 
tube formation assay. In hBMECs, CIP-expressing cells and OVCdk5, hypoxia 
79 
almost completely inhibited tube formation in hBMECs, Figure 3.11 (4). CIP-
expressing cells were still able to form tube-like structures under hypoxic conditions, 
Figure 3.11 (5). 
 
Figure 3-12 The effect of hypoxia on tube formation 
The effect of 24 hours incubation in hypoxia on hMBEC, CIP-expressing cells and OVCdk5 
tube formation compared to the normoxic condition. 
 
Two-Way ANOVA test was used to assess the effects of hypoxia and normoxia on 
a different type of cells and to assess the interaction between them. It showed a 
*significant increase in the number of tube formation in CIP-expression cells in 
hypoxia vs normoxia (p <0.05). 
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3.2.2.2.4 The Effect of DAPT on Tube Formation 
Cdk5 inhibition in the tube formation assay was performed during 24 hours in normal 
hBMECs, CIP-expressing cells and OVCdk5 in the presence or absence of the 
inhibitor (DAPT; 10uM). 
 
Figure 3-13 Images of tube formation assay on hBMECs CIP-expressing cells 
and OVCdk5 
1: Normal hBMECs control, 2: hBMECs positive control (treated with FGF-2), 3: hBMECs 
treated with DAPT (10µM), 4: hBMECs treated with DAPT and FGF-2, 5: OVCdk5 control, 
6: OVCdk5 treated with FGF-2, 7: OVCdk5 treated with DAPT and 8: OVCdk5 treated with 
DAPT and FGF-2. The experiments were performed in triplicate wells and repeated three 
times. 
The capillary tube formation was inhibited in OVCdk5, as seen by the reduction in 
tubule-like structures. The cells were not able to migrate to form new capillary 
structures in the presence of DAPT, Figure 3.13 (11), CIP-expressing cells did not 
have the same response compared to OVCdk5, the reason could be the biological 
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effect of CIP-expression is blocking apoptosis through the Cdk5/p25 signalling 
pathway, Figure 3.13 (7). 
Assays were performed during 24 hours of incubation with CDK5 inhibitor (DAPT; 
10µM), in hBMECs, CIP-expressing cells and OVCdk5. DAPT inhibited OVCdk5 
tube formation, as seen by the reduction in tubule-like structures, Figure 3.13 (11). 
The CIP-expressing cells were still maintained tube formation in the presence of 
DAPT, Figure 3.13 (7). 
  
Figure 3-14 The effect of the DAPT on cells under hypoxia 
The effect of DAPT on hBMECs, CIP-expressing cells and OVCdk5 tube formation after 24 
hours incubation in hypoxia, DAPT was used at the same concentration (10µM).  
Two-Way ANOVA test was used to assess the effects of various types of treatment 
on a different type of cells and to assess the interaction between treatments (FGF-
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2, DAPT, FGF-2 + DAPT) and type of cells (hBMEC, CIP and OVCdk5). It showed 
a **significant effect of DAPT treatments was observed on OVCdk5 compared to 
hBMECs, p<0.01. The experiments were performed in triplicate wells and repeated 
three times. 
 
3.2.2.2.5 hBMECs Spheroid Sprouting Assay 
Sprouting occurred from the spheroid core, and the sprout length was estimated 
with the Image-J software (using five spheroids with similar spheroid core sizes for 
each condition). The methylcellulose gel was prepared prior to the experiment 
 
Figure 3-15 CIP expression cells support in vitro spheroid sprouting during 
hypoxia 
1: hBMECs (normoxia), 2: CIP-expressing cells (normoxia), 3: OVCdk5 (normoxia), 4: 
hBMECs (hypoxia), 5: CIP-expressing cells (hypoxia) and 6: OVCdk5 (hypoxia). 
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Phase contrast images showing the impact of Cdk5 deregulation on spheroid cell 
sprouting under hypoxic (1% O2, 24 hours) compared to normoxic conditions. The 
image (Fig 3-15) shows that there were fewer sprouts from hBMECs (4) compared 
to CIP-expressing cells (5), but there were no sprouts from OVCdk5 (6) under 
hypoxia. In addition, there were a number of sprouts were seen from CIP-expressing 
cells (3) and it was also seen in hBMECs (1), but few in OVCdk5 under normal 
conditions. 
 
Figure 3-16 The effect of hypoxia on the spheroids sprouting 
The effect of 24 hours incubation in hypoxia on hBMECs, CIP-expressing cells and OVCdk5 
on spheroid sprouting compared to the normoxic condition. 
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Two-Way ANOVA test was used to assess the effects of hypoxia and normoxia on 
a different type of cells and to assess the interaction between them. It showed a 
significant (*: p<0.05) increase in the number of spheroid sprouting in CIP-
expressing cells in hypoxia vs normoxia. The experiments were performed in 
triplicate wells and repeated three times. 
 
3.2.3 Discussion 
Angiogenesis has various roles under pathological conditions. Resistance to 
angiogenesis by hypoxia may be overcome by the use of therapeutic targets 
directed to areas of ischaemic damage in the brain. This goal can only be 
implemented if we understand the pathological processes and molecular details of 
hypoxia-mediated damage and the molecular partners involved. To fulfil this aim, 
we tested angiogenesis in ECs incubated under hypoxic conditions. When ECs were 
cultured under stroke-mimicking conditions (hypoxia), there was no migration and/or 
tube formation due to oxygen deprivation. However, transfecting ECs with the Cdk5 
inhibitor peptide (CIP) under hypoxia allowed for migration and tube formation. This 
suggests 1) The protective role of CIP under hypoxic conditions allows migration 
and tube formation and 2) Hypoxia-mediated prevention of angiogenesis could be 
facilitated by Cdk5. Hence, we assume that Cdk5 is involved in hypoxia-mediated 
damage, and/or activated under hypoxic conditions to facilitate angiogenesis 
prevention. This phenomenon was previously confirmed by Liebl, who suggested 
the involvement of Cdk5 in regulating EC migration and angiogenesis (Liebl et al., 
2010). The results may promote the use of Cdk5 as a novel target for anti-
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angiogenic therapy. Inhibition of the Cdk5-p25 complex formation may enhance 
Cdk5 availability for p35 binding, hence leading to the activation of the small GTPase 
Rac1 and results in an organisation of the actin cytoskeleton as well as the formation 
of focal adhesion or the microtubules necessary for cell migration and angiogenesis 
(Liebl et al., 2010). Thus, p35 is directly associated with CIP action in inhibiting Cdk5 
(or its phosphorylated form), through some form of association (binding) with Cdk5. 
Evidence suggests that the apoptosis of neurons after a stroke is strongly 
associated with Cdk5 hyperactivation mediated by its activator p25 (Love, 2003). 
This, taken together with 1) the increased ratio of p35/p25 in CIP response to 
hypoxia and 2), the co-localisation of p35 and Cdk5 (which was also evident in CIP-
expressing ECs), suggests  that CIP inhibits Cdk5 through facilitating its binding and 
inactivation by p35, thus preventing Cdk5 from p25-binding and hyperactivation, 
which is implicated in stroke pathology. 
 
 
3.3 Cell Attachment and Spreading 
3.3.1 Introduction 
Previous studies have demonstrated the role of Cdk5 in the regulation of 
cytoskeleton dynamics and motility (Slevin et al., 2006), through the modulation of 
talin stability and cell migration (Huang et al., 2009). Thus, we investigated the 
interplay of Cdk5 and p35 with components that control cellular motility.  
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3.3.2 Results 
3.3.2.1 Cytoarchitectural Properties of Cdk5, Activated Cdk5 (pCdk5) 
and p35 
The co-localisation of p35 during spreading, culminated with the formation of focal 
clusters with Cdk5. Thus, p35 and p-Cdk5 were co-localised at the tips of actin fibres 
of hBMECs and CIP-expressing cells. These actin tips are linked to the directional 
movement of the spreading and movement of hBMECs. The co-localisation of p35 
and Cdk5 are in favour of the second scenario relating to p35 binding and/or 
inhibition of Cdk5 to prevent hypoxia-mediated damage. 
When activated during in early spreading (pCdk5 and p35), Cdk5 is localised at the 
tip of actin fibre (Figure 3.17). Figure-3.18 shows the active Cdk5 [pCdk5, pTyr(Ser15)] 
localised at actin tips (arrows) in early spreading. Figure-3.19 shows the pCdk5 co-
localisation in late spreading and Figure-3.20 shows the pCdk5 localisation and 
elongated moving. While Figure-3.21 shows p35 is co-localised with actin stress 
fibres in early stage moving, and Figure-3.22 shows the cell spreads in filament tips 
in late spreading cells. Moreover, the p35 localisation and elongated moving are 
demonstrated in Figure-3.23. 
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Figure 3-17 Cdk5 localisation with actin in hBMECs 
Confocal microscopy showing the Cdk5 localisation and early stage spreading. The 
merged magnification shows the Cdk5 is located on the tip of the actin fibre (arrow). 
 
Figure 3-18 Activated Cdk5 (pCdk5) localisation and early spreading 
Confocal microscopy showing pCdk5 [pTyr(Ser15)] localisation with actin tips 
(arrows) and fibres in early spreading in hBMECs. 
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Figure 3-19 pCdk5 Localisation and late spreading 
Confocal microscopy showing pCdk5 [pTyr(Ser15)] localisation with actin tips (arrows) and 
fibres in the late stage of spreading in hBMECs. 
 
 
 
Figure 3-20 pCdk5 Localisation and elongated moving in hBMECs 
Confocal microscopy is showing the pCdk5 localisation with actin tips (arrows) and fibre in 
elongated moving cells. 
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Figure 3-21 p35 localisation and early spreading in hBMECs 
Confocal microscopy showing the p35 (green) localisation with actin tips (arrow) and in the 
early stage of spreading cells. 
 
 
Figure 3-22 p35 localisation and late spreading in hBMECs 
Confocal microscopy showing p35 localisation with actin tips (arrows) and in the late stage 
of spreading cells. 
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Figure 3-23 p35 localisation and elongated moving 
Confocal microscopy showed the p35 localisation with actin tips (arrows) and elongated 
moving in hBMECs. 
 
The above representative images showing Cdk5 (Figure 3.17), pCDK5 (Figure 3.18, 
3.19, 3.20) and p35 (Figure 3.21, 3.22, 3.23) localisation at the tip of actin fibres 
(arrows) during cell spreads culminating in filament tips (arrows in merge). 
Immunofluorescence confocal microscope analysis. Objective 65x. Original 
magnification in the merge, x300. Bars, 25 μm. Each experiment was performed in 
triplicate. 
 
3.3.2.2 Roscovitine inhibited Cdk5 and p35 clustering with actin fibres 
and thereby blocking Cdk5 activity and p35 activity 
The inhibition of Cdk5 activity with roscovitine resulted in the delocalisation of pCdk5 
(Figure 3.24, 3.25) and p35 (Figure 3.26, 3.27) from actin filaments and stress fibres, 
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producing irregular cytoplasmic bundles with actin (arrows in magnification) in early 
and late spreading using hBMECs. 
 
Figure 3-24 Localisation of pCdk5 on F-Actin and merged magnification 
Immunofluorescence images showing the cytoplasmic bundles with actin (arrows in 
magnification) in early spreading hBMECs.  
 
Figure 3-25 Localisation of pCdk5 on F-Actin and merged magnification 
Immunofluorescence images showing cytoplasmic bundles with actin (arrows in 
magnification) in late spreading in hBMECs. 
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Figure 3-26 Localisation of p35 on F-Actin and merged magnification 
Immunofluorescence images showing cytoplasmic bundles with actin (arrows in 
magnification) in early spreading in hBMECs. 
 
Figure 3-27 Localisation of p35 on F-Actin and merged magnification 
Immunofluorescence images showing cytoplasmic bundles with actin (arrows in 
magnification) in late spreading in hBMECs. 
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Figure 3-28 Impaired formation of talin tips and their co-localisation with p35 
and integrin β-1 by roscovitine in hBMECs 
Confocal microscopy showed talin tips and the co-localisation with p35 and integrin β-1 in 
hBMECs 
All of the above representative images showing the inhibition of Cdk5 activity by 
roscovitine on actin fibres (arrows) in early spreading that resulting in the 
delocalisation of pCdk5 (Figure 3.24, 3.25), and p35 (Figure 3.26, 3.27) from actin 
filaments and stress fibres, producing irregular cytoplasmic bundles with actin 
(arrows in magnification). Roscovitine also impairs formation of talin tips and their 
co-localisation with p35 and integrin β1 (Figure 3.28). Immunofluorescence confocal 
microscope analysis. Objective 65x. Original magnification in merge, x200. Bars, 25 
μm. Each experiment was performed in triplicate. 
 
3.3.2.3 p-Cdk5, p35/actin intracellular co-localisation during hypoxia 
Confocal microscopy showing the images of Cdk5 activity was blocked by 
roscovitine. 
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Figure 3-29 p35 and actin intracellular co-localization in hBMECs during 
hypoxia 
Immunofluorescence image shows the effect of hypoxia on p35 intracellular distribution with 
actin filaments and fibres in hBMECs. Under hypoxia, p35 lost its canonical filament-like 
structure organisation (arrows in merge magnification,) and localisation at actin fibre tips, 
showing a more diffuse cytoplasmic distribution. 
 
 
Figure 3-30 Co-localisation of p35 on Actin and merged magnification in CIP 
expressing cells in hypoxia 
Images show the p35 intracellular co-localisation with actin filaments and fibre tips in CIP 
expressing cells under hypoxia (arrows in magnification image). 
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Figure 3-31 Localisation of Cdk5 on Actin and merged magnification in 
hBMECs control in hypoxia 
Images show Cdk5 maintained its intracellular co-localization with actin fibre tips in hBMECs 
in hypoxia (arrows in merge magnification). 
 
Figure 3-32 Localisation of Cdk5 on Actin and merged magnification in CIP 
expressing cells in hypoxia 
Confocal immunofluorescence Images showing the Cdk5 intracellular localisation with actin 
filaments and fibres from the effects of hypoxia in CIP expressing cells. 
Distribution of actin filaments and fibres in hBMECs in hypoxia. Cdk5 maintained its 
co-localisation with actin fibre tips (arrows in the merge, Figure 3.31). Compared to 
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the controls CIP insertion protected p35 (Figure 3.30) and Cdk5 (Figure 3.32) 
intracellular localisation with actin filaments and fibres from the effects of hypoxia. 
 
3.3.3 Discussion 
p35 localisation alongside during spreading culminated with the formation of focal 
clusters with Cdk5. Thus, p35 and p-Cdk5 were co-localised at the end tips of actin 
fibres of ECs and CIP-expressing ECs. These actin tips are linked to the directional 
movement of the spreading and movement of ECs. The co-localisation of p35 and 
Cdk5 are in favour of the second scenario relating to p35 binding and/or inhibition 
of Cdk5 to prevent hypoxia-mediated damage. Thus, p35 is directly associated with 
CIP action in inhibiting Cdk5 (or its phosphorylated form), through some form of 
association (binding) with Cdk5. The phosphorylated form of active Cdk5 (p-Cdk5) 
and p35 were previously reported to be associated with integrin β-1 and talin, 
directed to the formation of microvesicles in late-spreading and elongated cells as 
well as being localised at the focal tips of actin stress fibres (Qiao et al., 2008; Liebl 
et al., 2010; He et al., 2011). 
 
Evidence suggests that the apoptosis of neurons after stroke is strongly associated 
with Cdk5 hyperactivation mediated by its activator p25 (Love, 2003). This, taken 
together with 1) the increased ratio of p35/p25 in CIP response to hypoxia and 2) 
the co-localisation of p35 and Cdk5 (which was also evident in CIP-expressing 
cells), makes us propose that CIP inhibits Cdk5 through facilitating its binding and 
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inactivation by p35, thus preventing Cdk5 from p25-binding and hyperactivation, 
which is implicated in stroke conditions. 
The aim here was to investigate the role of Cdk5 in the attachment and spreading 
of ECs (normal vs. CIP-transfected). The cytoskeletal dynamics were investigated 
using immunofluorescent staining in the presence of roscovitine (an inhibitor of 
Cdk5). 
 
3.4 Western blotting 
3.4.1 Introduction 
Following brain ischemia, the rise in neuronal death by Cdk5 hyperactivation is 
mediated by p25 in hypoxia (Hayashi et al., 1999; Love, 2003). The signal 
transduction cascade leads to the activation of calpains, a group of calcium-
activated cytosolic proteases, that cleave p35 to the more stable p25 peptide, 
thereby hyperactivating Cdk5 and mediating neuronal apoptosis (Shi et al., 2012; 
Barros-Miñones et al., 2013). The rationale for co-incubating ECs and CIP-
transfected ECs under hypoxia with calcium was due to the role of increased Ca2+ 
in stroke (activation of caspases and proteases such as calpain). Thus, we aimed 
to mimic or trigger stroke not only by hypoxia but also by increasing the intracellular 
[Ca2+] content. This would help us explain the effects of Cdk5 and how calpain (a 
protease that is associated with increased levels of calcium) is involved in stroke-
mediated damage. 
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To examine the signal transduction pathway(s) underpinning Cdk5 action and 
calpain activation under stroke conditions (hypoxia and elevated calcium), protein 
targets involved in mediating apoptosis cellular survival and angiogenesis were 
examined. The role of CIP in protecting hBMECs under hypoxia was also tested. 
Western blotting techniques were utilised to explain the differences (if any) in the 
protein expression profiles related to normal and hypoxic conditions within hBMECs, 
CIP-expressing cells and OVCdk5. 
α-tubulin is an intracellular subunit of the tubulin protein that is common in 
eukaryotes and makes up microtubules which are a component of the cytoskeleton. 
It is involved in determining cell structure and providing platforms for intracellular 
transport, including some forms of cell locomotion, the intracellular transport of 
organelles, and the separation of chromosomes of during mitosis and meiosis 
(Cooper, 2000; Ndhlovu et al., 2011). In Western blotting, it is essential to correct 
for protein loading and factors, such as transfer efficiency using normalisation 
against housekeeping proteins (Ferguson et al., 2005). Therefore, in this study, α-
tubulin was used as a loading control for Western blotting. 
 
3.4.2 Results 
The results from Ca2+-treated hBMECs suggest that the relative active caspase-3 
expression in hBMECs in the presence of Ca2+ is higher than CIP-expressing cells 
in the presence of Ca2+. In normoxia, the p-ERK1/2 expression is similar after 5-min 
in hBMECs (Ca2+-treated) and CIP-expressing cells (untreated), but higher in CIP-
expressing cells treated with Ca2+. And in normoxia, the p-Cdk5 expression is 
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induced in Ca2+-treated hBMECs and CIP-expressing cells in a time-dependent 
manner, with levels being higher in control hBMECs. 
 
3.4.2.1 Expressions of p35 and p25 in hypoxia and normoxia 
hBMECs and CIP-expressing cells were cultured under hypoxic and normoxic 
conditions for 24 hours and the relative density of protein expression was analysed 
using free software Image J. α-tubulin was used as a loading control. These results 
show that the CIP-expressing cells had a higher p35/p25 ratio compared to the 
normal cells in hypoxia (B4 versus B3) Fig 3-33. 
 
Figure 3-33 Expressions of p35/p25 ratio in hypoxia and normoxia 
 
A) 1: hBMECs (normoxia), 2: CIP-expressing cells (normoxia), 3: hBMECs (hypoxia) 
and 4: CIP-expressing cells (hypoxia). 
B) Calculated results are reported in the graph (B); relative density of p35/p25 protein 
ratio in control hBMECs and in CIP-expressing cells determined in normoxic and hypoxic 
conditions. The bar chart represents the relative protein expression compared to the control 
(=1.0), and the experiment was repeated at least twice.  
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3.4.2.2 Relative expression of Hsp70 under Normoxic and Hypoxic 
Conditions 
hBMECs were cultured under hypoxic and normal conditions, and the relative 
density of protein expression was analysed using free software Image-J. The bar 
chart shows that heat shock protein 70 (HSP70) was up-regulated (increased by 1 
fold) in hBMECs under hypoxic conditions. The bars represent the standard 
deviations, and the experiment was repeated at least twice.  
 
Figure 3-34 Western blot showing that HSP70 was up-regulated weakly under 
hypoxia compared to the control 
A) 1: Normoxia, 2: Hypoxia. 
B) The results indicated that the hypoxic condition caused cellular metabolic 
deprivation, which was effective oxygen deficiency used as this in vitro stroke model. 
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3.4.2.3 The Relative expression of Hsp70 in HBMECs and CIP-
expressing cells under normoxic and hypoxic condition 
hBMECs and CIP-expressing cells were analysed under hypoxic and normoxic 
conditions and the relative density of protein expression was analysed using Image-
J. 
 
Figure 3-35 Representative Western blot showing the expression of HSP70 in 
hBMECs and CIP-expressing cells under normoxic and hypoxic conditions 
A) 1: hBMECs (normoxia), 2: hBMECs (hypoxia), 3: CIP-expressing cells (normoxia), 
4: CIP-expressing cells (hypoxia). 
B) The results indicated that the expression of HSP70 was up-regulated in hBMECs, 
but it was down-regulated in CIP-expressing cells under hypoxic conditions. The bar chart 
represents the relative protein expression compared to the control (=1.0), and the 
experiment was repeated at least twice. 
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3.4.2.4 Expression of p35/p25 in hBMECs, CIP-expressing cells and 
OVCdk5 in normoxia 
hBMECs, CIP-expressing cells and OVCdk5 were cultured under normal conditions 
(Figure 3.36 A, normoxia) and the relative density of protein expression was 
analysed using free software Image-J (Figure 3.36 B). 
 
Figure 3-36 Representative Western blot showing p35/p25 expression in 
hBMECs, CIP-expressing cells and OVCdk5 under normoxic condition 
A) 1: hBMECs, 2: OVCdk5 and 3: CIP-expressing cells. 
B) In CIP-expressing cells, the levels of p25 showed a decrease compared to control 
hBMECs. And in OVCdk5, the levels of p25 showed an increase compared to control. The 
bar chart represents the relative protein expression compared to the control (=1.0), and the 
experiment was repeated at least twice. 
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3.4.2.5 Expression of p35/p25 in hBMECs, CIP-expressing Cells and 
OVCdk5 in hypoxia 
hBMECs, CIP-expressing cells and OVCdk5 were cultured under the hypoxic 
condition for 24 hours and the p35/25 expressions were analysed by Western 
blotting (Figure 3.37 A). The relative density of protein expression was analysed 
using Image-J (Figure 3.37 B). 
  
Figure 3-37 Representative Western blot showing p35/p25 expression in 
hypoxia 
A) 1: hBMECs, 2: OVCdk5 and 3: CIP-expressing cells. 
B) The Levels of p25 shows the lowest expression in CIP-expressing cells under 
hypoxic condition, but the p35 expression stays similar level in CIP-expressing cells 
compared to control cells in hypoxia. The bar chart represents the relative protein 
expression compared to the control (=1.0), and the experiment was repeated at least twice. 
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3.4.2.6 Relative active Caspase-3 expression in the presence of Ca2+ in 
different times 
hBMECs and CIP-expressing cells were cultured (Figures 3.38A, 3.39A and 
3.40A).And the relative density of protein expression was analysed using Image-J 
(Figure 3.38B, Figure 3.39, Band Figure 3.40B). The untreated cells were used as 
controls.  
 
Figure 3-38 Representative Western blot showing the effect of Ca2+ on active 
Caspase-3 expression for 5 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells in 
the absence of Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). 
B) hBMECs cells and CIP-expressing cells treated with Ca2+ (5µM) for 5 mins. The level 
of active caspase-3 expression showed an increase in treated hBMEC s (A2 and B2) (19 
fold, B2)) and CIP-expressing cells (9 fold, A4 and B4) compared to control (untreated cells 
A1, B1 and A2, B2) respectively. The bar chart represents the relative protein expression 
compared to the control (=1.0), and the experiment was repeated at least twice. 
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Figure 3-39 Relative active Caspase-3 expressions in the presence of Ca2+ for 
15 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells 
untreated with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). 
B) The representative Western blot (Figure 3.39A) shows the effect of Ca2+ (5µM) on 
active Caspase-3 expression in hBMECs and CIP-expressing cells treated with Ca2+ for 15 
mins. Both hBMECs and CIP-expressing cells, the level of active caspase-3 expression was 
increased (A2, B2 and A4, B4) compared to control (1 and 3) (untreated CIP-expressing 
cells, A1, B1 and A3, B3). The bar chart represents the relative protein expression 
compared to the control (=1.0), and the experiment was repeated at least twice.  
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Figure 3-40 Relative active Caspase-3 expressions in the presence of Ca2+ for 
40 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells 
untreated with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). 
B) Representative Western blot showing the effect of active Caspase-3 expression, 
hBMECs (B2) and CIP-expressing cells treated with Ca2+ (5µM) for 40 mins, again, in 
treated CIP-expressing cells, the level of active caspase-3 expression showed an increase 
compared to control (untreated CIP-expressing cells , A4, B4, as did hBMECs (A2, B2 
versus A1, B1). The bar chart represents the relative protein expression compared to the 
control (=1.0), and the experiment was repeated at least twice.  
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3.4.2.7 p-ERK1/2 expression in hBMECs in the presence of Ca2+ in 
different times 
hBMECs and CIP-expressing cells were treated with Ca2+ (5µM) for 5, 15 and 40 
mins respectively. Untreated cells were used as controls (Figures 3.41A, 3.42A and 
3.43A) and the relative density of protein expression was analysed using Image-J 
(Figures 3.41B, 3.42B and 3.43B). 
 
Figure 3-41 Representative Western blot showing the effect of phospho-
ERK1/2 in hBMECs and CIP-expressing cells treated with Ca2+ for 5 mins. 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells 
untreated with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). 
B) The levels of phospho-ERK1/2 showed an increase both in treated hBMECs (B2)   and 
CIP-expressing cells (B4) compared to control (untreated hBMECs and CIP-expressing 
cells) (B4 vs B3). The bar chart represents the relative protein expression compared to the 
control (=1.0), and the experiment was repeated at least twice. 
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Figure 3-42 Representative Western blot showing the effect of phospho-
ERK1/2 in hBMECs and CIP expressing cells treated with Ca2+ for 15 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells 
untreated with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). 
B) In treated CIP-expressing cells, the level of Phospho-ERK1/2 showed an increase 
compared to control (untreated CIP-expressing cells). But the level of Phospho-ERK1/2 
showed a decrease compared to control (untreated hBMECs). The bars represent the 
standard deviations, and the experiment was repeated at least twice. 
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Figure 3-43 Representative Western blot showing the effect of phospho-
ERK1/2 in hBMECs and CIP-expressing cells treated with Ca2+ for 40 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells 
untreated with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). 
B) In treated CIP-expressing cells, the level of phospho-ERK1/2 showed an increase 
(A4 and B4) compared to control [untreated CIP-expressing cells (A3 and B3)], but the level 
of phospho-ERK1/2 showed a decrease (A2 and B2) compared to control (untreated 
hBMECs, A1 and B1). The bars represent the standard deviations, and the experiment was 
repeated at least twice. 
  
110 
3.4.2.8 p-Cdk5 Overexpression in hBMECs in Hypoxia 
hBMECs were incubated in hypoxic condition for 24 hours, the cells incubated in 
normoxic condition were used as a control. The relative density of protein 
expression was analysed using Image-J (Figure 3.44B). 
 
Figure 3-44 Representative Western blot showing the expression of p-Cdk5 
in hypoxia samples 
Under hypoxic conditions, the level of p-Cdk5 showed an increase of 3.8 fold (B2 vs B1) 
compared to normoxia control. The bar chart represents the relative protein expression 
compared to the control (=1.0), and the experiment was repeated at least twice.  
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3.4.2.9 p35 Expression in hBMECs in Hypoxia 
hBMECs were incubated under hypoxic conditions for 24 hours, and the cells 
incubated under normoxic conditions were used as a control. The relative density of 
protein expression was analysed using Image-J (Figure 3.45B). 
 
Figure 3-45 Representative Western blot showing the expression of p35 in 
normoxia and hypoxia samples 
In hypoxia, the level of p35 showed an increase (0.8 fold, B2 vs B1) compared to normoxia 
control. The bar chart represents the relative protein expression compared to the control 
(=1.0), and the experiment was repeated at least twice.  
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3.4.2.10 p35 expression in hBMECs and CIP-expressing cells in the 
presence of calpain 
hBMECs and CIP-expressing cells were treated with calpain (10µg/ml) for 30 mins. 
The relative density of protein expression was analysed using Image-J (Figure 
3.46B). The cells untreated with calpain were used as a control.  
 
Figure 3-46 Representative Western blot showing the effect on p35 
expression, with calpain-treated cells for 30 mins 
A) 1: hBMECs control, 2: hBMECs treated with calpain (10µg/ml), 3: CIP-expressing 
cells untreated control, 4: CIP-expressing cells treated with calpain (10µg/ml). 
B) In CIP-expressing cells (B4) treated with calpain, the level of p35 expression showed 
a 2-fold increase compared to control cells (untreated hBMECs, B1). The bar chart 
represents the relative protein expression compared to the control (=1.0), and the 
experiment was repeated at least twice. 
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3.4.2.11 Capase-3 expression in hBMECs and CIP-expressing cells under 
hypoxic conditions 
hBMECs and CIP-expressing cells were incubated under hypoxic conditions for 24 
hours, and the cells incubated in normoxic conditions were used as a control. The 
relative density of protein expression was analysed using Image-J (Figure 3.47B). 
 
Figure 3-47 Expression of caspase-3 in hBMECs and CIP-expressing cells 
under normoxic and hypoxic conditions 
A) 1: hBMECs (normoxia), 2: hBMECs (hypoxia), 3: CIP-expressing cells (normoxia) 
and 4: CIP-expressing cells (hypoxia). 
B) hBMECs were incubated for 24 hours under hypoxic conditions, the expression of 
caspase-3 was significantly higher (5.8 fold, A2 and B2) compared to the cells in normoxic 
conditions. In CIP- expressing cells, the level of caspase-3 expression was higher (1.5 fold, 
A4 and B4) when exposed to 24 hours of hypoxia compared to CIP-expressing cells under 
normal conditions, but lower than in the control cells (A2 and B2). The bar chart represents 
the relative protein expression compared to the control (=1.0), and the experiment was 
repeated at least twice. 
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3.4.2.12 p-Cdk5 expression in hBMECs and CIP-expressing cells in the 
presence of Ca2+ 
hBMECs and CIP-expressing cells were treated with Ca2+ (5µM) for 5, 15 and 40 
mins respectively. The untreated cells were used as a control. The relative density 
of protein expression was analysed using free software Image-J (Figures 3.48B, 
3.49B and 3.50B) 
 
Figure 3-48 Representative Western blot showing the effect of p-Cdk5 
expression, with Ca2+ treated for 5 mins in hBMECs and CIP-expressing cells 
1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells untreated 
with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). The bar chart represents the 
relative protein expression compared to the control (=1.0), and the experiment was repeated 
at least twice.  
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The level of p-Cdk5 expression showed an increase in Ca2+-treated cells compared 
to untreated cells (A" and B" vs A1 and B1, A4 and B4 vs A3 and B3)  
 
Figure 3-49 Representative Western blot shows the effect of p-Cdk5 
expression, with Ca2+-treated cells for 15 mins 
1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells untreated 
with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). The bar chart represents the 
relative protein expression compared to the control (=1.0), and the experiment was repeated 
at least twice. 
 
The level of p-Cdk5 expression shows an increase in Ca2+-treated cells compared 
to untreated cells, A2 and B2 vs A1 and B1, A4 and B4 vs A3 and B3. 
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Figure 3-50 Representative Western blot showing the effect of p-Cdk5 
expression, with Ca2+ treated cells for 40 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells 
untreated with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). 
B) The level of p-Cdk5 expression shows an increase in Ca2+-treated CIP-expressing 
cells compared to untreated CIP-expressing cells (A4 and B4 vs A3 and B3). The bars 
represent the standard deviations, and the experiment was repeated at least twice. 
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3.4.2.13 p-CDK5 Expression in cells treated with Ca2⁺ in different times 
hBMECs, CIP-expressing cells and OVCdk5 were cultured and treated with the Ca2+ 
(5µM) calcium ionophore A23187 for 5, 15 and 40 mins respectively. The cells not 
with Ca2+were used as controls (Figures 3.53A, 3.54A and 3.55A). The relative 
density of protein expression was analysed using Image-J (Figures 3.51B, 3.52B 
and 3.53B). 
 
Figure 3-51 Representative Western blot showing the effect of Ca2+ on p-
Cdk5 expression in hBMECs, CIP-expressing cells and OVCdk5 treated with 
Ca2+ for 5 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells 
untreated with Ca2+, 4: CIP-expressing cells treated with Ca2+ (5µM), 5: OVCdk5 untreated 
with Ca2+ and 6: OVCdk5 treated with Ca2+ (5µM). 
B) In treated hBMECs and CIP-expressing cells, the level of p-Cdk5 expression 
showed a slight increase compared to untreated cells (A2 and B2 vs A1 and B1, A4 and B4 
vs A3 and B3), but in treated OVCdk5, the level of p-Cdk5 was greatly increased compared 
to untreated cells (A6 and B6 vs A5 and B5). The bar chart represents the relative protein 
expression compared to the control (=1.0), and the experiment was repeated at least twice. 
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Figure 3-52 Representative Western blot shows the effect of Ca2+ treatment 
on p-Cdk5 expression in hBMECs, CIP-expressed cells and OVCdk5 for 15 
mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells 
untreated with Ca2+, 4: CIP-expressing cells treated with Ca2+ (5µM), 5: Overexpressing 
Cdk5 transfectants untreated with Ca2+ and 6: OVCdk5 treated with Ca2+ (5µM). 
B) In treated cells, the level of p-Cdk5 expression showed a slight increase compared 
to untreated cells (A2 and B2 vs A1 and B1), but there was a large increase in OVCdk5 (A5 
and B5) and a small increase between treated OVCdk5 cells and untreated cells (A6 and 
B6 vs A5 and B5). The bar chart represents the relative protein expression compared to the 
control (=1.0), and the experiment was repeated at least twice. 
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Figure 3-53 Representative Western blot showing the effect of Ca2+ treatment 
on p-Cdk5 expression for 40 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells 
untreated with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM), 5: OVCdk5 
untreated with Ca2+ and 6: OVCdk5 treated with Ca2+ (5µM). 
B) In treated hBMECs and CIP-expressing cells, the level of p-Cdk5 expression 
showed a slight increase compared to untreated cells (A2 and B2 vs A1 and B1, A4 and B4 
vs A3 and B3), but in treated OVCdk5 cells, the level of p-Cdk5 showed a large increase 
compared to untreated cells (A6 and B6 vs A5 and B5). The bar chart represents the relative 
protein expression compared to the control (=1.0), and the experiment was repeated at least 
twice. 
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3.4.2.14 P35 Expression in cells treated with Ca2⁺ in different times 
hBMECs and CIP-expressing cells were cultured and treated with Ca2+ (5µM) for 5, 
15 and 40 mins respectively (Figures 3.54A, 3.55A and 3.56A).The relative density 
of protein expression was analysed using Image-J (Figures 3.56B, 3.57B and 
3.58B). The untreated cells were used as controls. 
 
Figure 3-54 Representative Western blot showing the effect on p35 
expression of Ca2+ for 5 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP expressing cells 
untreated with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). 
B) hBMECs were treated with Ca2+ (5µM) for 5 mins. In Ca2+-treated CIP-expressing 
cells, the level of p35 expression showed a 5-fold increase compared to the untreated CIP-
expressing cells. The bars represent the standard deviations, and the experiment was 
repeated at least twice. 
The effect of cells play no roles of p35 activity. It was unable to show clear changes 
in expression and break down the level in calcium-treated samples, however, in the 
same samples, phosphorylation of Cdk5 was changed by Ca2+. Although it could 
not show p25, as it is very difficult to see p25 level. Struggling throughout the project 
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to see changes in the amount of the protein but indirectly it has been shown that 
caspase and p-Cdk5 particularly substrate.  
 
Figure 3-55 Representative Western blot showing the effect of p35 
expression, with Ca2+ treated cells for 15 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP-expressing cells 
untreated with Ca2+ and 4: CIP-expressing cells treated with Ca2+ (5µM). 
B) There is 1.8 fold increase in p35 expression in hBMECs treated with Ca2+ (5µM), but 
there is a slight increase in CIP-expressing cells treated with Ca2+ (A2 and B2 vs A1 and 
B1, A4 and B4 vs A3 and B3). The bar chart represents the relative protein expression 
compared to the control (=1.0), and the experiment was repeated at least twice. 
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Figure 3-56 Representative Western blot showing the effect of p35 
expression in hBMECs treated with Ca2+ for 40 mins 
A) 1: hBMECs control, 2: hBMECs treated with Ca2+ (5µM), 3: CIP expressing cells 
untreated with Ca2+ and 4: CIP expressing cells treated with Ca2+ (5µM). 
B) In Ca2+ treated CIP-expressing cells, the level of p35 expression showed about an 
8-fold increase compared to the untreated cells (A4 and B4 vs A3 and B3), but there was 
no significant difference between the hBMECs (A2 and B2 vs A1 and B1). The bar chart 
represents the relative protein expression compared to the control (=1.0), and the 
experiment was repeated at least twice. 
 
3.4.2.15 p35 Expression in hBMECs treated with Ca2+ and calpain 
hBMECs were cultured and treated with Ca2+ (5µM) and calpain (10µg/ml) 
respectively for 30 mins. The untreated hBMECs were used as controls (Figure 
3.57A) and the relative density of protein expression was analysed using Image-J 
(Figure 3.57B). α-tubulin was used as a loading control. 
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Figure 3-57 p35 expression in hBMECs treated with calpain and Ca2+ for 30 
mins 
A) 1: hBMECs control, 2: hBMECs treated with calpain (10µg/ml) and 3: hBMECs 
treated with Ca2+ (5µM). 
B) Representative Western blot showing the p35 expression in hBMECs treated with 
calpain (10µg/ml) and Ca2+ (5µM) for 30 mins. The calpain- treated cells had a 0.45-fold 
decrease in p35 expression (A2 and B2 vs A1 and B1). The level of p35 expression showed 
a 5-fold decrease in Ca2+-treated cells compared to controls (A3 and B3 vs A1 and B1). The 
bar chart represents the relative protein expression compared to the control (=1.0), 
and the experiment was repeated at least twice. 
 
3.4.3 Discussion 
The protein expression profiles of ECs under hypoxic conditions show an up-
regulation of HSP-70 and caspase-3 (key proteins involved in apoptosis) and a 
downregulation of p35. This suggests that hypoxia induces apoptosis through HSP-
70- and caspase-3-mediated pathways and that these pathways are dependent on 
the down-regulation and/or inhibition of p35. The evidence from this study suggests 
that CIP-expressing ECs reverse the actions of hypoxia through promoting p35 
expression and reducing HSP-70 and caspase-3 and/or inhibiting their activity. This 
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implies that CIP exhibited resistance to hypoxia through 1) blocking apoptosis and 
2) mediating p35-mediated pathways and/or by increasing the ratio of p35/p25 in 
response to hypoxia. Hence, two scenarios exist for CIP action (inhibition of Cdk5) 
under hypoxia: 1) inhibition of Cdk5 blocks the mechanism of apoptosis and/or 2) 
due to its high levels, p35 binds to and/or inhibits Cdk5 hypoxia-mediated damage. 
 
Ca2+-treatment at 5µM induces caspase-3 expression in ECs and CIP-expressing 
ECs under normoxia with this being time-dependent (decreases with time). 
Caspase-3 activation has been shown to trigger necrosis and apoptosis, and to 
exacerbate cerebral oedema and neuronal death after intracerebral haemorrhage 
(Wang et al., 2013). It was previously demonstrated that increases in intracellular 
calcium are involved in the activation of one or more families of proteases and 
possibly other degradative enzymes (Criddle et al., 2004) and that this is associated 
with cell death (Orrenius et al., 2003). Calcium overload was also suggested as one 
of the mechanisms for neuronal degeneration after an excitotoxic insult (Bano and 
Nicotera, 2007). CIP protects ECs from Ca2+-induced caspase-3 expression 
suggesting a mechanism in which CIP blocks apoptosis and/or caspase-3 
expression under normal conditions. CIP-expressing cells induce p-ERK 1/2 
expression 40 mins after Ca2+ incubation in normal conditions and immediately (with 
a time-dependent increase), under conditions of increased [Ca2+]. This is the second 
mechanism of CIP protection by enhancing the cellular proliferation marker (p-
ERK1/2). ERK activity has been associated with neurodegenerative diseases and 
brain injury following ischaemia in animal models (Cagnol and Chambard, 2010). 
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Under conditions of increased [Ca2+], ECs have reduced p-ERK1/2 levels, providing 
a mechanism for enhanced cellular damage. The increase in p-Cdk5 is a sign of EC 
protection under increased [Ca2+], with CIP-expressing cells promoting its 
expression 40 mins after the elevation of Ca2+. This phenomenon is also true in 
OVCdk5 cells treated with Ca2+. CIP protection, through p-Cdk5, means a third 
mechanism for CIP protection. Also, it means that p-Cdk5 is the form of Cdk5 
involved in mediating cellular protection under stroke conditions. Thus, in combined 
elevated Ca2+ and hypoxic conditions, p-35 expression coincides with the results 
from the p-Cdk5, which leads us to conclude that it is the p35-Cdk5 that is driving 
the cellular protective response to elevated Ca2+ levels. The results from the 
downregulation of p-35 expression under hypoxia and upregulation in the presence 
of CIP means that the protection of p-35/Cdk5 is also present in hypoxia and 
therefore stroke (since hypoxia and elevated Ca2+ represent two states of the stroke 
condition) (Aarts et al., 2003). The reduction of p-25 in presence of CIP means that 
CIP is preventing the conversion of p35 into p25 by calpain-dependent proteolysis 
of p25, thus inactivating the pathological role and the mislocalisation of Cdk5 by 
releasing it from p-25 and binding it to p35. Without CIP, Cdk5-p25 kinase 
hyperphosphorylated tau disrupts the cytoskeleton and promotes the apoptosis of 
primary neurons (Polster and Fiskum, 2004). 
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Stroke is one of the major causes of death and disability in developing countries. It 
takes place when the blood supply to a fraction of the brain is abruptly interrupted 
or severely reduced by, for instance, a blood clot. This is known as an ischaemic 
stroke. Hence, a detailed understanding of the mechanisms involved in the 
pathogenesis of stroke can provide a platform for therapeutic intervention and the 
adaptation of strategies to prevent the disease. 
A number of studies indicate that deregulation of a set of cell cycle kinases has been 
implicated in neural death following an ischaemic insult and in neurodegenerative 
disorders. Here, it was highlighted Cdk5 and its two activators, the p35/p25 
peptides, may act as potential critical players in neural survival, via support of 
revascularisation/angiogenesis. Below, the particular novel findings of the work and 
current literature and further hypotheses are highlighted. 
 
4.1 A Role for Cdk5 in Cellular Attachment and Spreading 
This study demonstrates that Cdk5 activation through its major substrate, p35, 
provides a key trigger for the initiation and maintenance of in vitro brain ECs 
angiogenesis and that this interaction and signalling cascade are crucial for ensuring 
correct cytoskeletal arrangement. While the activation of Cdk5 through p35 is 
associated with cytoprotection (Shi et al., 2012), as evident in this study, Cdk5 
hyper-activation mediated by the cleaved p35 fragment, p25, and initiated via 
calpains is associated with neuronal cytoskeletal derangement, neuronal apoptosis 
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and cell death during ischaemic brain insult, similar to other observations (Love, 
2003). 
 
Cdk5 activity is regulated by synthesis and degradation of p35. p35, the activator of 
Cdk5, is a short-lived protein with a half-life of 20 to 30 minutes. A balance of 
synthesis and degradation controls the amount of the p35 protein. It can be 
degraded by the ubiquitin-proteasome pathway. The Cdk5/p35 complex is involved 
in multiple cellular functions such as differentiation, migration and angiogenesis 
(Kanungo et al., 2009; Liebl et al., 2010). In addition, previous work has shown that 
the incorporation of the inactive form of Cdk5 to developing neurones inhibited 
neurite outgrowth, and this could be relevant to stroke recovery (Lai et al., 2014). 
It has been investigated the interplay of Cdk5 and p35 with classical molecular 
players of the control of mechanical forces and motility in EC. It was found a specific 
time/spatial interaction of active (phosphorylated) Cdk5 (p-Cdk5) and p35 with 
integrin β1 and talin, directed to the formation of microvesicles in late-spreading and 
elongated/moving cells. This observation was also evident where p35, Cdk5 and 
pCdk5 were localised at the focal tips of actin stress fibres (Huang et al., 2009; Liebl 
et al., 2010; He et al., 2011). Inhibition of this interaction, by roscovitine or in DN-
mutants in our cellular model blocked cell protrusion and stable adhesions. Notably, 
the p35 localisation alongside actin fibres during spreading was time-dependent, 
hence longer time incubation leads to higher levels of localisation and culminated 
with the formation of focal clusters with Cdk5.  
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Under pathological conditions of cell stress or injury, calcium influx activates calpain, 
which in turn cleaves p35 to generate p25. This study was conducted to evaluate 
the ratio of p35/p25 in normoxic and hypoxic conditions. The degradation of p35 
accompanied by the increase in abundance of p25 during hypoxic conditions 
suggest increased Cdk5/p25 ratio in cells under stress. The Cdk5/p25 complex 
contributes directly to cell death and pathogenesis of stroke (Kanungo et al., 2009). 
p25 in this scenario is responsible for the negative activation of Cdk5 and thus its 
subsequent involvement in the cellular death, opposing the actions of the Cdk5/p35 
complex in directing cellular proliferation. Hence, the ratio of p35/p25 in cells 
determines the availability and ratio of Cdk5/p35 over Cdk5/p25 and thus promotion 
of either cellular proliferation or apoptosis.  
 
4.2 Cdk5 Directly Promoted Cellular Migration and Angiogenesis 
The results from this current study demonstrate that Cdk5 stimulated angiogenesis 
through cellular migration. It was suggested that Cdk5 and its activator proteins (e.g. 
p35) mediate migration through the phosphorylation of a variety of targets (Paterson 
and Courtneidge, 2017). The role of the p35 proteins is attributed to their presence 
within the plasma membrane at the cytoplasmic projection regions to assist cell 
motility as previously shown (Kanungo et al., 2009). Cdk5 may mediate migration 
through the phosphorylated regulation of Smurf1 binding to talin head (TH), thereby 
controlling TH turnover and adhesion stability leading to cell migration (Schaefer et 
al., 2012).  
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Upon talin proteolysis by Cdk5 phosphorylation, talin head ubiquitination and 
degradation are inhibited, thereby limiting focal adhesion turnover (promoting focal 
adhesion disassembly) and stabilising lamellipodia at the leading edges that, in turn, 
leads to cell migration mediated Smurf1-induced ubiquitination and degradation (Xie 
et al., 2013). A study by Demelash et al. also confirmed the presence of p35 in 
nuclear, cytoplasmic, and membranous locations using primary lung cancer cells as 
a model (Demelash et al., 2012). This study suggests that Cdk5 promotes the 
expression and upregulation of the p35 gene(s) hence the presence of p35 within 
the nucleus. It was previously reported that the expression of the p35gene, as well 
as other genes involved in cellular migration, was regulated by neurogenic bHLH 
genes (Ge et al., 2006).  
Here, the Cdk5-dependent hBMECs migration was preserved during hypoxia in 
those overexpressing Cdk5, but not in normal cells. Such a protective role of Cdk5 
has previously in hypoxia in vitro (Kang et al., 2015). This effect of Cdk5 may be 
attributable to its ability to induce the expression of actin, microtubules and 
intermediate filament cytoskeletal components, which modulate cell adhesion, 
transport and intracellular signalling (Dhavan and Tsai, 2001). 
Indeed, a study by Dhavan and Tsai suggests the involvement of Cdk5 and its 
activator, p35 in promoting neuronal migration and neurite outgrowth in actin 
polymerisation by PAK1, downregulation by PAK1 hyperphosphorylation through 
Cdk5 in a RAC-dependent manner using neuronal cells (Dhavan and Tsai, 2001;  
He et al., 2016). The latter process is complex and involves the contribution from 
the Rho family of GTPases and the PAK kinases. Furthermore, Cdk5 may indirectly 
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promote migration via the associated inhibition of p35-Cdk5 with β-catenin and N-
cadherin (Dhavan and Tsai, 2001; Nguyen et al., 2002), which are implicated in 
neuronal adhesion and aggregation (Takeichi et al., 1990; Chalasani et al., 2005). 
Also shown here is that calpain decreased ECs migration; this may be due to the 
minor role of p25 in the regulation of Cdk5 during endothelial migration, although 
our current experimental data cannot really explain the mechanisms of this finding. 
 
4.3 Inhibition Studies to Elucidate Mechanisms of Cdk5 Migration 
When the Notch signalling inhibitor; DAPT was used, ECs and OVCdk5 migration 
were significantly reduced, as previously reported (Chen et al., 2015). DAPT has 
been shown to suppress Cdk5 activity and to modulate the distribution of 
cytoskeletal proteins in rat cortical neurons (Kanungo et al., 2008; Inestrosa et al., 
2011). Hence, it was suggested that the inhibition of migration is due to the 
disruption of Cdk5/p35 interaction linked somehow through Notch signalling 
pathways (Kanungo et al., 2008; Pozo and Bibb, 2016). The latter also 
demonstrated the role of Cdk5 in forming a component in modulating Notch 
signalling and the role it may play in cytoskeletal protein arrangements and hence, 
neuronal development and survival. Furthermore, Cdk5 as well as acting through 
Notch was shown to phosphorylate integrin β-1, talin (Bosutti et al., 2013), 
neurofilaments and tau protein, involved in organisation/dynamics, cell spreading 
and subsequent cell migration (Ackerley et al., 2003; Shea et al., 2004; 
Compagnucci et al., 2016;). Thus, DAPT attenuation of Cdk5 activity may have led 
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to the reduced phosphorylation state of cytoskeletal proteins and their subsequent 
distribution. 
FGF-2 in our cell migration assays also promoted Cdk5-dependent hBMECs 
migration. FGF-2 enhances cell differentiation and thus leads to cellular migration 
(Slevin and Krupinski, 2009), however, in this case, the increased Cdk5-dependent 
hBMECs migration may also be attributed to the effect of FGF-2 in upregulating the 
activity of Cdk5 (Ding et al., 2011). Although the impact of FGF-2 on Cdk5 activity 
was not measured in this current study, the latter may have important therapeutic 
implications when used in vivo to enhance the Cdk5 action and hence cellular 
survival under stroke conditions and/or CNS development to recover from the 
chronic effects of stroke. 
 
4.4 The Pathophysiological Role of Cdk5-Possible 
Activators/Inhibitors under Hypoxia 
The results in this thesis show that under normal conditions Cdk5 induces cell 
migration. The latter is reduced under the hypoxic condition similar to control. The 
overexpression of p35 in our ECs in hypoxia was previously confirmed by Mitsios et 
al., where Cdk5 and p35/p25 were shown to be concomitantly overexpressed in ECs 
in hypoxic regions of stroke tissue (Mitsios et al., 2007). 
The latter phenomenon suggests that the balance of signalling between these 
pathways defines cellular fate in relation to angiogenesis or cell protection after 
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stroke (Slevin and Krupinski, 2009). The increase in the expression of p35 by 
overexpressed Cdk5 might provide some protection of the latter cells under hypoxic 
conditions. Overexpressed Cdk5 means there is more available to bind p35 and so 
competing against p25, so in effect, less aberrant p25 binding would occur. 
Overexpressed Cdk5 was demonstrated to have an effect on increasing the stability 
of p35 by 2 to 3 fold (Patrick et al., 1998; Corbel et al., 2015). The molecular 
mechanisms that underlie the higher ratio of p35/p25 association with OVCdk5 in 
hypoxia remain unknown. 
 
4.5 CIP Inhibited Calpain-dependent Cdk5/p25-mediated Effects 
It has been shown previously that excessive activation of calpain contributes to 
ischaemic neurodegeneration, neurotrauma and necrotic death (Liebl et al., 2010). 
Cdk5 hyper-activation mediated by the cleaved p35 fragment, p25, and initiated via 
calpain was shown to be associated with neuronal cytoskeletal derangement, 
neuronal apoptosis, and cell death during ischaemic brain insult (Love, 2003). This 
study confirms that the calcium-activated proteolytic enzyme, calpain is associated 
with an increased in the level and expression of p25 (the truncated product of p35) 
and abnormal Cdk5 activation by p25, as previously demonstrated (Amini et al., 
2013). 
The Ca2+-activated protease calpain decreases the p35 availability and in this way 
contribute to the balance between cellular apoptosis and/or death in the normal 
situation. The results suggest a transient decrease in the expression of Cdk5 
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provoked by Ca2+ suggesting that calpain may play a role in this decrease. The Ca2+-
induced rise p-ERK expression followed a similar time course as that of Cdk5, which 
disappeared after 40 minutes of incubation in Ca2+. In CIP overexpressing cells, the 
duration of increased p-ERK expression was prolonged, as was the reduction in 
Cdk5, suggesting a role of CIP in promoting p-ERK expression, activation of calpain 
and reduction in Cdk5 expression. 
It has been demonstrated that the ratio of p35/p25 in CIP-expressing cells was up-
regulated in response to hypoxia and exhibited resistance to hypoxia, which is 
involved in cell protection and angiogenesis. The results were as consistent with 
previous studies reporting the altered balance of p25/p35-Cdk5 signalling in favour 
of p35 in vitro in hBMECs during hypoxic conditions (Bosutti et al., 2013). Hence, 
the co-expression of CIP with p25 can reduce p25 mediated activation of Cdk5. 
The results confirmed the role of CIP in increasing p35 bio-availability under hypoxic 
conditions while decreasing p25, as compared to normal controls. The CIP, 
Cdk5/p25 inhibitory peptide, is a derivative fragment of p35, which binds with high 
affinity to Cdk5. CIP competes with p25 for Cdk5 causing an inhibition of Cdk5/p25 
activity without affecting the Cdk5/p35 ratio in vitro. The effects of CIP on inducing 
neuronal regeneration and inhibiting neuronal apoptosis have been demonstrated 
(Zheng et al., 2002; Zheng et al., 2005), but its protective effect in ECs has not been 
reported. It is suggested that CIP could protect ECs from hypoxia; the mechanism 
may involve the inhibition of the activity of Cdk5/p25. The 15 minutes incubation 
period may be insufficient for the expression of p-Cdk5 by CIP. The disorganised 
tube formation in our p-Cdk5 cells upon the inhibition of the p-35-Cdk5 axis may be 
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due to the decrease in the activity of the small GTPase Rac1, as previously 
suggested, leading to the disorganisation of the actin cytoskeleton (Liebl et al., 
2010). 
Linked to brain damage and neurodegeneration, it is believed that Cdk5/p25 directly 
phosphorylates the tau protein, which enhances cytoskeletal derangement (Lloret 
et al., 2015) and its endogenous activators, p35 and p25, regulate its activity. It was 
reported that forced expression of CIP inhibits Cdk5/p25 activity, preventing the 
phosphorylation of tau in neurons, thereby reversing the actions of calpain (Zheng 
et al., 2005; KOSARAJU, 2013). Therefore, it was suggested a possible additional 
function/use of CIP may be to act indirectly to reduce tau phosphorylation that could 
lead to a decrease in the neurofibrillary tangles and/or enhanced tube formation. 
Indeed, the use of the Cdk5 inhibitory peptide, CIP, in our case may reverse the 
process of neurodegeneration and neurofibrillary tangles triggered by calpain 
leading to an increase in the levels p35 and cellular survival signals, including Cdk5-
mediated regulation of endothelial cell migration and angiogenesis (Liebl et al., 
2010). 
Furthermore, it has been shown that CIP reduces the expression of Heat shock 
protein 70 (HSP70, 70 kDa) and caspase-3 thus promoting cellular survival against 
apoptosis in vitro. Heat shock proteins are molecular chaperones, which guide 
protein folding and are involved in cellular transport. They can be upregulated in 
response to cellular stress, but some are also constitutively expressed (Conway, 
2003). HSP70 was shown to bind to and enhance the degradation of Cdk5-
hyperphosphorylated tau (Mietelska-Porowska et al., 2014). Thus, the down-
136 
regulation of expression of the HP70 by CIP can be protective against tau protein 
phosphorylation by Cdk5 and thus promote EC migration (Kesavapany et al., 2007). 
Caspases, also known as interleukin 1β-converting enzyme (ICE)-like proteases, 
play key biological roles in inflammation and mammalian apoptosis (Loppnow et al., 
2013), while CIP has a neuroprotective role in dissociating Cdk5 from p25, 
promoting the binding of Cdk5 to p35 (Ji et al., 2017). 
The most intensively studied apoptotic caspase is caspase-3, which normally exists 
in the cytosolic fraction of cells as an inactive precursor that is activated by 
proteolysis during apoptotic cell death (Kavanagh et al., 2014). Caspase-3 can be 
activated by multiple apoptotic signals and has been shown to promote hypoxia-
dependent cellular apoptosis (Hua et al., 2005). Caspase-3 expression, enzymatic 
activity and cleavage of its substrates inhibition were found to reduce DNA 
fragmentation and brain tissue loss (Han et al., 2002; Toulmond et al., 2004; 
McIlwain et al., 2013). 
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Figure 4-1 A schematic representation displaying a model for the 
mechanism of hypoxia-induced toxicity through calpain cleavage of the Cdk5-
p35 complex 
Hence, it is logical to believe that the reduction of caspase-3 expression through 
CIP can be protective against stroke-induced hypoxia and may display a therapeutic 
potential. P-ERK was demonstrated to have a long-term role in promoting vascular 
cell survival, and these findings indicate the protective role of CIP in reversing the 
activity of the Cdk5-p25 cytotoxic pathway. The involvement of ERK in the early 
growth response (EGR-1)-induced expression of p35, may explain the protective 
role of the latter in promoting cellular survival in CIP cells under hypoxia  (Dhavan 
and Tsai, 2001; Sun et al., 2013). Hence, this study suggests that CIP mediates its 
protective role through decreasing the expression of HSP70 and caspase-3 and 
enhancing the expression of ERK (Figure 4.1). 
Specifically, regarding EC/angiogenesis, after stroke, the presence of CIP appears 
to abrogate hypoxia and calpain-induced apoptosis at the same time allowing 
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vascularization to continue. Hence, during the remodelling phase of stroke, a more 
effective production of functional/patent microvessels within the penumbra region 
and sub-core of the infarct, following the release of growth factors and cytokines 
during the inflammatory phase, could lead to greater functional brain tissue recovery 
and reduce patient disability. Therefore a proposal for the use of CIP or a derivative 
of CIP as a therapeutic protection agent after stroke may be a viable possibility. 
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Chapter 5 Conclusions 
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 Findings from this study suggest that Cdk5 promotes an increase in the ratio 
p35/ p25 similar to that induced by CIP, thereby indicating CIP may have a 
protective role under hypoxic-stroke-mimicking conditions and could help 
therapeutically in reducing cellular/vascular apoptosis whilst improving tissue 
remodelling and angiogenesis. 
 Cell morphological studies indicate the role of Cdk5 in sprout formation which 
under hypoxic conditions and in the presence of DAPT inhibitor is inhibited. 
This confirms a pre-angiogenic role for normal Cdk5 signalling pathways. 
 Cdk5 promoted tube formation. Hence the overexpression of Cdk5 under 
hypoxic conditions may lead to cellular cytoskeletal rearrangement and aid 
the process of angiogenesis. However, an imbalance between the later 
mechanisms leads to Cdk5/p25 dependent apoptosis. 
 CIP may determine the cellular fate and/or the degree of cell protection. 
Hence, this indicated the critical role of the p35/Cdk5 pathway in controlling 
cell dynamics of brain EC and general protection of brain cells against 
apoptosis under hypoxic conditions. CIP may be a potential therapeutic for 
acute stroke treatment with multiple positive attributes, therefore. Activation 
of p35/Cdk5 signalling at the expense of p25-Cdk5 plays a protective role in 
hypoxic conditions and positively contributes to preserving cell motility and 
the proper spatial and temporal control of cytoskeletal dynamics, which is 
essential for successful angiogenesis - mechanisms linking Cdk5 to cell 
attachment and movement have been described here. 
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 Taken together we suggest that the protective roles of CIP are mediated 
through the down-regulation of HSP-70 and caspase-3 (key proteins involved 
in apoptosis) and up-regulation of p-ERK (a marker for cellular survival and 
proliferation). 
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Chapter 6 Future prospects 
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The results from the present study indicate a protective role of CIP via promoting 
endothelial cell survival through enhancing the expression of ERK and reducing the 
caspase-3 and HSP70. Hence, CIP can display a potential therapeutic for 
individuals suffering a stroke.  
 
Further studies are needed to account for the role of CIP as well as Cdk5 in stroke 
and adapt strategies to modulate their role in vivo. 
 
Future studies could be employed to target specific substrates of Cdk5 linked to 
apoptosis, such as tau, p53, caspase 3 and Bax, thereby inhibiting their interaction 
with Cdk5, hence bypassing their cytotoxic pathways. 
 
Future studies may also employ animal stroke models/studies to target both CIP 
and Cdk5 in real time in vivo. Kinase inhibitors (such as roscovitine) are not specific 
inhibitors of Cdk5-p25 but also of Cdk5-p35 and other Cdks, leading to potential side 
effects and reduced therapeutic efficacy. In order to overcome this problem, several 
peptides consisting of amino acid residues of p35, such as CIP (a peptide of 125 
amino acid residues), p10 and p5, have been generated and can specifically reduce 
Cdk5-p25 hyperactivity. Stroke recovery would be monitored using MRI imaging 
platforms and recovery measurements as well as histology. 
 
Nanoparticle-mediated drug loading, delivery and/or release strategies might be 
used to deliver CIP and/or active analogues to specific stroke tissues in a 
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nanoparticle-guided manner (e.g. superparamagnetic iron oxide). Studies could 
also be aimed at inhibiting the activity of the Cdk5-p25 complex. Previous studies 
have used truncated peptides of p35; P5, which is a 24-residue mimetic peptide of 
the p35 C-terminal and a more readily diffusible peptide through the blood-brain 
barrier. It can specifically inhibit p25-Cdk5 activity similar to CIP but was found 
ineffective for inhibiting the normal endogenous p35-Cdk5 activity. Strategies could 
also be targeted at blocking the cleavage of p35 to p25 by calpain to reduce its 
cytotoxic effects in vivo. 
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Chapter 7 Appendices 
1. CIP Sequence 378bp 
TGCCTGGGTGAGTTTCTCTGCCGCCGGTGCTACCGCCTGAAGCACCTGTCC
CCCACGGACCCCGTGCTCTGGCTGCGCAGCGTGGACCGCTCGCTGCTTCTG
CAGGGCTGGCAGGACCAGGGCTTCATCACGCCGGCCAACGTGGTCTTCCTC
TACATGCTCTGCAGGGATGTTATCTCCTCCGAGGTGGGCTCGGATCACGAGC
TCCAGGCCGTCCTGCTGACATGCCTGTACCTCTCCTACTCCTACATGGGCAA
CGAGATCTCCTACCCGCTCAAGCCCTTCCTGGTGGAGAGCTGCAAGGAGGC
CTTTTGGGACCGTTGCCTCTCTGTCATCAACCTCATGAGCTCAAAGATGCTGC
AGATAAATGCC 
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2. Construction of pcDNA3-CIP-GFP expression vectors 
 
CIP DNA fragments were gained by PCR from pLV-CIP plasmids, the primers were 
5’-TTAG GATCCTTGCCTGGGTGAGTTTC-3’ and 5’-
GTCGGATCCTCATGGGTCGGCATTTATC-3’. PCR product digested by BamH I 
(Invitrogen) was inserted into pcDNA3-GFP vectors by T4 ligation reaction. After 
transformation positive clones were screened by PCR, finally verified DNA 
sequence and reading frame through sequencing. 
Transfecting hBMEC and selecting stable expression cell clones Using TransIT-
2020 (Mirus) pcDNA3-CIP-GFP was transfected into hBMECs in 6-well plates. 260 
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µL of DNA complex including 2.5 µg plasmids and 7.5 µL TransIT-2020 reagents in 
EBM-2 medium was added to 80% confluence cells of each well. After transfection 
24 hrs, cells were trypsinized and seeded in 48-well plates at different dilutions in 
EGM-2 medium containing 500 µg/ml Geneticin (GIBCO). The transfected cells 
were selected under the drug medium for next 4 weeks. Resistant clones were 
transferred into 6-well plates and were detected GFP fluorescent signals under 
fluorescence microscopy and the level of CIP mRNA by RT-PCR. All RT-PCR 
reagents were from Invitrogen, the RNAs of cell clones were isolated by TRIzol; RT 
reaction was carried out following Company’s protocol including using 2.5 µg of 
RNA, 1 µl of SuperScript II and 1 µl of 50 µM random primer in 20 µl volume. 5 µl of 
cDNA was used for PCR reaction, CIP primers were the same as PCR clone 
primers, 18S rRNA as a housekeeping gene, primers were 5’-
TAGAGGGACAAGTGGCGTTC-3’ and 5’-TGTACAAAGGGCAGGGACTT-3’. 
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Expression of GFP fluorescent marker in CIP-17 clone transferred with pcDNA-GFP-CIP 
 
The levels of CIP mRNA in hBMEC clones transferred with pcDNA-GFP-CIP using RT-PCR 
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3. Chamber Used for Hypoxia Assay. 
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